CleftGeneDB-Search

Gene: MDM2

Basic information

Tag	Content
Uniprot ID	Q00987; A6NL51; A8K2S6; Q13226; Q13297; Q13298; Q13299; Q13300; Q13301; Q53XW0; Q71TW9; Q8WYJ1; Q8WYJ2; Q9UGI3; Q9UMT8;
Entrez ID	4193
Genbank protein ID	AAA75516.1; AAA75514.1; BAF83030.1; AAL40179.1; AAF42995.1; AAM78554.1; AAA82061.1; AAA82237.1; AAA60568.1; AAL40180.1; AAA75518.1; AAP35922.1; CAB64448.1; CAA78055.1; AAA75517.1; AAA75515.1;
Genbank nucleotide ID	XM_006719399.3; NM_001278462.1; XM_005268872.4; NM_001145339.2; NM_002392.5;
Ensembl protein ID	ENSP00000353611; ENSP00000258149; ENSP00000444430; ENSP00000377065; ENSP00000299252;
Ensembl nucleotide ID	ENSG00000135679
Gene name	E3 ubiquitin-protein ligase Mdm2
Gene symbol	MDM2
Organism	Homo sapiens
NCBI taxa ID	9606
Cleft type
Developmental stage
Data sources	Homology search
Reference
Functional description	E3 ubiquitin-protein ligase that mediates ubiquitination of p53/TP53, leading to its degradation by the proteasome. Inhibits p53/TP53- and p73/TP73-mediated cell cycle arrest and apoptosis by binding its transcriptional activation domain. Also acts as a ubiquitin ligase E3 toward itself and ARRB1. Permits the nuclear export of p53/TP53. Promotes proteasome-dependent ubiquitin-independent degradation of retinoblastoma RB1 protein. Inhibits DAXX-mediated apoptosis by inducing its ubiquitination and degradation. Component of the TRIM28/KAP1-MDM2-p53/TP53 complex involved in stabilizing p53/TP53. Also component of the TRIM28/KAP1-ERBB4-MDM2 complex which links growth factor and DNA damage response pathways. Mediates ubiquitination and subsequent proteasome degradation of DYRK2 in nucleus. Ubiquitinates IGF1R and SNAI1 and promotes them to proteasomal degradation (PubMed:12821780, PubMed:15053880, PubMed:15195100, PubMed:15632057, PubMed:16337594, PubMed:17290220, PubMed:19098711, PubMed:19219073, PubMed:19837670, PubMed:19965871, PubMed:20173098, PubMed:20385133, PubMed:20858735, PubMed:22128911). Ubiquitinates DCX, leading to DCX degradation and reduction of the dendritic spine density of olfactory bulb granule cells (By similarity). Ubiquitinates DLG4, leading to proteasomal degradation of DLG4 which is required for AMPA receptor endocytosis (By similarity).
Sequence	MCNTNMSVPT DGAVTTSQIP ASEQETLVRP KPLLLKLLKS VGAQKDTYTM KEVLFYLGQY 60 IMTKRLYDEK QQHIVYCSND LLGDLFGVPS FSVKEHRKIY TMIYRNLVVV NQQESSDSGT 120 SVSENRCHLE GGSDQKDLVQ ELQEEKPSSS HLVSRPSTSS RRRAISETEE NSDELSGERQ 180 RKRHKSDSIS LSFDESLALC VIREICCERS SSSESTGTPS NPDLDAGVSE HSGDWLDQDS 240 VSDQFSVEFE VESLDSEDYS LSEEGQELSD EDDEVYQVTV YQAGESDTDS FEEDPEISLA 300 DYWKCTSCNE MNPPLPSHCN RCWALRENWL PEDKGKDKGE ISEKAKLENS TQAEEGFDVP 360 DCKKTIVNDS RESCVEENDD KITQASQSQE SEDYSQPSTS SSIIYSSQED VKEFEREETQ 420 DKEESVESSL PLNAIEPCVI CQGRPKNGCI VHGKTGHLMA CFTCAKKLKK RNKPCPVCRQ 480 PIQMIVLTYF P 491

Abbreviation :
CLO : cleft lip only. CPO : cleft palate only. CLP : cleft lip and palate. CL/P : cleft lip with/without cleft palate.
For humans: CL/P, CLO, CPO, and CLP. For mice: CLO, CLP, and CPO.

Gene expression information

Gene expression in different tissues (GTEx V7)

Gene expression in different tissues (ENCODE)

Protein structural annotations

3D structure in PDB database

PDB ID
1RV1
1T4E
1T4F
1YCR
1Z1M
2AXI
2C6A
2C6B
2F1Y
2FOP
2GV2
2HDP
2LZG
2M86
2MPS
2RUH
2VJE
2VJF
3EQS
3G03
3IUX
3IWY
3JZK
3JZR
3JZS
3LBK
3LBL
3LNJ
3LNZ
3MQS
3TJ2
3TPX
3TU1
3V3B
3VBG
3VZV
3W69
4DIJ
4ERE
4ERF
4HBM
4HFZ
4HG7
4JV7
4JV9
4JVE
4JVR
4JWR
4MDN
4MDQ
4OAS
4OBA
4OCC
4ODE
4ODF
4OGN
4OGT
4OGV
4OQ3
4QO4
4QOC
4UD7
4UE1
4UMN
4WT2
4XXB
4ZFI
4ZGK
4ZYC
4ZYF
4ZYI
5AFG
5C5A
5HMH
5HMI
5HMK
5J7F
5J7G
5LAV
5LAW
5LAY
5LAZ
5LN2
5MNJ
5OAI
5OC8
5SWK
5TRF
5UMM
5VK0
5WTS
5XXK
5Z02
5ZXF
6AAW
6GGN
6H22
6I29
6I3S
6IM9
6KZU
6Q96
6Q9H
6Q9L
6Q9O
6T2D
6T2E
6T2F
2C6A
2LZG
3LBK
4ODF
4WT2
4XXB
5MNJ

Protein disorder information

Orthologous information

Relation	Gene symbol	Entrez ID	UniProt ID	Cleft type	Species	Evidence	Details
1:1 ortholog	MDM2	540378	F1MYE6		Bos taurus	Prediction	More>>
1:1 ortholog	MDM2	102173163	A0A452FBR9		Capra hircus	Prediction	More>>
1:1 ortholog	MDM2	4193	Q00987		Homo sapiens	Prediction	More>>
1:1 ortholog	Mdm2	17246	P23804	CPO	Mus musculus	Publication	More>>
1:1 ortholog	MDM2	742141	A0A2I3TD93		Pan troglodytes	Prediction	More>>
1:1 ortholog	Mdm2	314856	A0A0G2JVC1		Rattus norvegicus	Prediction	More>>
1:1 ortholog	mdm2		B0R0S9		Danio rerio	Prediction	More>>

Other genetic variants/mutations

ID	Variant	Type	Disease	Chromosome\Coordinate	Evidence
rs1347430167	p.Thr4Ile	missense variant	-	NC_000012.12:g.68809222C>T	gnomAD
rs781195441	p.Ser7Phe	missense variant	-	NC_000012.12:g.68809231C>T	ExAC,gnomAD
rs201821879	p.Pro9Leu	missense variant	-	NC_000012.12:g.68809237C>T	ESP,ExAC,TOPMed,gnomAD
rs1450828029	p.Thr10Ala	missense variant	-	NC_000012.12:g.68809239A>G	gnomAD
rs199663735	p.Asp11Glu	missense variant	-	NC_000012.12:g.68809244T>A	ExAC,gnomAD
rs991848363	p.Ala13Val	missense variant	-	NC_000012.12:g.68809249C>T	TOPMed,gnomAD
rs1183704933	p.Val14Gly	missense variant	-	NC_000012.12:g.68809252T>G	TOPMed
rs749406013	p.Thr16Ala	missense variant	-	NC_000012.12:g.68809257A>G	ExAC,gnomAD
rs771046322	p.Ile19Thr	missense variant	-	NC_000012.12:g.68809267T>C	ExAC,gnomAD
rs1361311287	p.Glu23Lys	missense variant	-	NC_000012.12:g.68809278G>A	gnomAD
rs1361311287	p.Glu23Gln	missense variant	-	NC_000012.12:g.68809278G>C	gnomAD
rs1246173207	p.Glu25Gln	missense variant	-	NC_000012.12:g.68809284G>C	TOPMed
rs746439458	p.Glu25Gly	missense variant	-	NC_000012.12:g.68809285A>G	ExAC,gnomAD
rs772554005	p.Thr26Ile	missense variant	-	NC_000012.12:g.68809288C>T	ExAC,TOPMed,gnomAD
rs772554005	p.Thr26Asn	missense variant	-	NC_000012.12:g.68809288C>A	ExAC,TOPMed,gnomAD
rs1295572460	p.Leu27Val	missense variant	-	NC_000012.12:g.68809290C>G	gnomAD
rs1470334779	p.Val28Ile	missense variant	-	NC_000012.12:g.68813554G>A	TOPMed
rs1330733959	p.Arg29Lys	missense variant	-	NC_000012.12:g.68813558G>A	gnomAD
rs1226240451	p.Leu35Ser	missense variant	-	NC_000012.12:g.68813576T>C	gnomAD
rs777599995	p.Val41Ala	missense variant	-	NC_000012.12:g.68813594T>C	ExAC
rs1321827832	p.Val41Ile	missense variant	-	NC_000012.12:g.68813593G>A	gnomAD
rs563762756	p.Asp46Glu	missense variant	-	NC_000012.12:g.68813610C>G	1000Genomes,ExAC,gnomAD
rs1487823798	p.Thr47Ser	missense variant	-	NC_000012.12:g.68813611A>T	gnomAD
rs1385829631	p.Arg65Gln	missense variant	-	NC_000012.12:g.68816849G>A	TOPMed,gnomAD
rs759244097	p.Lys70Met	missense variant	-	NC_000012.12:g.68816864A>T	ExAC,gnomAD
rs774100788	p.Lys70Gln	missense variant	-	NC_000012.12:g.68816863A>C	ExAC,TOPMed,gnomAD
rs1229293747	p.Leu81Val	missense variant	-	NC_000012.12:g.68816896C>G	gnomAD
rs764034976	p.Gly83Glu	missense variant	-	NC_000012.12:g.68816903G>A	ExAC,gnomAD
rs753663917	p.Phe86Cys	missense variant	-	NC_000012.12:g.68816912T>G	ExAC,gnomAD
rs761546875	p.Gly87Arg	missense variant	-	NC_000012.12:g.68816914G>C	ExAC,gnomAD
rs751618188	p.Tyr104Cys	missense variant	-	NC_000012.12:g.68820345A>G	ExAC,gnomAD
rs1257607973	p.Asn111Lys	missense variant	-	NC_000012.12:g.68820367T>G	gnomAD
rs767475639	p.Asn111Ser	missense variant	-	NC_000012.12:g.68820366A>G	ExAC,TOPMed,gnomAD
rs1287052048	p.Ser115Pro	missense variant	-	NC_000012.12:g.68824365T>C	gnomAD
rs567563488	p.Ser116Leu	missense variant	-	NC_000012.12:g.68824369C>T	1000Genomes,ExAC,TOPMed,gnomAD
rs1267194269	p.Gly119Arg	missense variant	-	NC_000012.12:g.68824377G>C	TOPMed
rs1320937462	p.Thr120Ile	missense variant	-	NC_000012.12:g.68824381C>T	gnomAD
rs1330649346	p.Val122Met	missense variant	-	NC_000012.12:g.68824386G>A	gnomAD
rs777635548	p.Asn125Ser	missense variant	-	NC_000012.12:g.68824396A>G	ExAC,gnomAD
rs770802264	p.Leu129Phe	missense variant	-	NC_000012.12:g.68824407C>T	ExAC,gnomAD
rs1318570880	p.Gly132Arg	missense variant	-	NC_000012.12:g.68824416G>C	TOPMed
rs774014032	p.Ser133Thr	missense variant	-	NC_000012.12:g.68824420G>C	ExAC,TOPMed,gnomAD
rs1227694909	p.Asp134Val	missense variant	-	NC_000012.12:g.68824423A>T	TOPMed
rs759861388	p.Gln135Glu	missense variant	-	NC_000012.12:g.68824425C>G	ExAC,TOPMed,gnomAD
rs1189496985	p.Glu141Asp	missense variant	-	NC_000012.12:g.68824569G>T	TOPMed
rs375992646	p.Leu142Pro	missense variant	-	NC_000012.12:g.68824571T>C	ESP,ExAC,TOPMed,gnomAD
rs752222682	p.Glu145Gln	missense variant	-	NC_000012.12:g.68824579G>C	ExAC,gnomAD
rs1294351700	p.Glu145Gly	missense variant	-	NC_000012.12:g.68824580A>G	gnomAD
rs1313246462	p.Pro147Thr	missense variant	-	NC_000012.12:g.68824585C>A	gnomAD
rs1225544458	p.His151Arg	missense variant	-	NC_000012.12:g.68824598A>G	TOPMed
rs1340897471	p.Ser157Cys	missense variant	-	NC_000012.12:g.68824616C>G	TOPMed
rs770763010	p.Thr158Ser	missense variant	-	NC_000012.12:g.68824618A>T	ExAC,gnomAD
rs1424278368	p.Arg162Thr	missense variant	-	NC_000012.12:g.68824631G>C	gnomAD
rs1297853240	p.Ala164Ser	missense variant	-	NC_000012.12:g.68824636G>T	TOPMed
rs778784299	p.Glu167Asp	missense variant	-	NC_000012.12:g.68824647G>C	ExAC,gnomAD
rs745584012	p.Thr168Ile	missense variant	-	NC_000012.12:g.68824649C>T	ExAC,gnomAD
rs1373817480	p.Glu169Gly	missense variant	-	NC_000012.12:g.68828771A>G	TOPMed
rs745680967	p.Asn171Asp	missense variant	-	NC_000012.12:g.68828776A>G	ExAC,gnomAD
rs375746507	p.Asn171Ser	missense variant	-	NC_000012.12:g.68828777A>G	ESP,ExAC,TOPMed,gnomAD
rs764554024	p.Ser172Leu	missense variant	-	NC_000012.12:g.68828780C>T	gnomAD
rs138567205	p.Asp173Gly	missense variant	-	NC_000012.12:g.68828783A>G	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs372899015	p.Gly177Ser	missense variant	-	NC_000012.12:g.68828794G>A	ESP,TOPMed
rs576062594	p.Arg179Gln	missense variant	-	NC_000012.12:g.68828801G>A	1000Genomes,ExAC,TOPMed,gnomAD
rs576062594	p.Arg179Pro	missense variant	-	NC_000012.12:g.68828801G>C	1000Genomes,ExAC,TOPMed,gnomAD
rs776774609	p.Arg181Lys	missense variant	-	NC_000012.12:g.68828807G>A	ExAC,gnomAD
rs1194693256	p.Arg183His	missense variant	-	NC_000012.12:g.68828813G>A	TOPMed
rs1555187172	p.Arg183Cys	missense variant	-	NC_000012.12:g.68828812C>T	-
RCV000649880	p.Arg183Cys	missense variant	Accelerated tumor formation, susceptibility to (ACTFS)	NC_000012.12:g.68828812C>T	ClinVar
rs748134261	p.His184Asn	missense variant	-	NC_000012.12:g.68828815C>A	ExAC,TOPMed,gnomAD
rs748134261	p.His184Tyr	missense variant	-	NC_000012.12:g.68828815C>T	ExAC,TOPMed,gnomAD
rs1252636313	p.Asp187Gly	missense variant	-	NC_000012.12:g.68828825A>G	TOPMed
rs1241409542	p.Ile189Val	missense variant	-	NC_000012.12:g.68828830A>G	gnomAD
rs370504060	p.Ile189Ser	missense variant	-	NC_000012.12:g.68828831T>G	ESP,ExAC,gnomAD
rs1369872407	p.Ser192Cys	missense variant	-	NC_000012.12:g.68828840C>G	TOPMed
rs766801308	p.Glu195Gly	missense variant	-	NC_000012.12:g.68828849A>G	ExAC,TOPMed,gnomAD
rs763423670	p.Glu195Lys	missense variant	-	NC_000012.12:g.68828848G>A	ExAC,gnomAD
rs774688124	p.Ser196Asn	missense variant	-	NC_000012.12:g.68828852G>A	ExAC,gnomAD
rs763587937	p.Leu199Val	missense variant	-	NC_000012.12:g.68828860C>G	ExAC,TOPMed,gnomAD
rs756673959	p.Val201Gly	missense variant	-	NC_000012.12:g.68828867T>G	ExAC,gnomAD
rs764783109	p.Ile202Val	missense variant	-	NC_000012.12:g.68828869A>G	ExAC,TOPMed,gnomAD
rs1321816960	p.Glu204Asp	missense variant	-	NC_000012.12:g.68828877G>T	gnomAD
rs750452466	p.Ile205Leu	missense variant	-	NC_000012.12:g.68828878A>T	ExAC,TOPMed,gnomAD
rs750452466	p.Ile205Leu	missense variant	-	NC_000012.12:g.68828878A>C	ExAC,TOPMed,gnomAD
rs750452466	p.Ile205Val	missense variant	-	NC_000012.12:g.68828878A>G	ExAC,TOPMed,gnomAD
RCV000531653	p.Ile205Leu	missense variant	Accelerated tumor formation, susceptibility to (ACTFS)	NC_000012.12:g.68828878A>C	ClinVar
rs1429670022	p.Cys206Arg	missense variant	-	NC_000012.12:g.68828881T>C	gnomAD
rs1429051105	p.Cys207Tyr	missense variant	-	NC_000012.12:g.68828885G>A	gnomAD
rs1464729148	p.Arg209Gly	missense variant	-	NC_000012.12:g.68828890A>G	TOPMed
rs1270017676	p.Ser210Thr	missense variant	-	NC_000012.12:g.68828894G>C	gnomAD
rs758396646	p.Ser211Arg	missense variant	-	NC_000012.12:g.68828896A>C	ExAC,gnomAD
rs780006768	p.Ser212Gly	missense variant	-	NC_000012.12:g.68828899A>G	ExAC,TOPMed,gnomAD
rs1261288897	p.Ser212Asn	missense variant	-	NC_000012.12:g.68828900G>A	gnomAD
rs1322919983	p.Ser213Asn	missense variant	-	NC_000012.12:g.68828903G>A	gnomAD
rs746732648	p.Thr218Ala	missense variant	-	NC_000012.12:g.68828917A>G	ExAC,gnomAD
rs755256189	p.Thr218Met	missense variant	-	NC_000012.12:g.68828918C>T	ExAC,TOPMed,gnomAD
rs1387843274	p.Pro222Leu	missense variant	-	NC_000012.12:g.68828930C>T	gnomAD
rs1352233718	p.Leu224Arg	missense variant	-	NC_000012.12:g.68835833T>G	TOPMed
rs758413036	p.Leu224Val	missense variant	-	NC_000012.12:g.68835832C>G	ExAC,gnomAD
rs766375101	p.Ala226Thr	missense variant	-	NC_000012.12:g.68835838G>A	ExAC,gnomAD
rs766375101	p.Ala226Ser	missense variant	-	NC_000012.12:g.68835838G>T	ExAC,gnomAD
rs1392233926	p.Gly227Ala	missense variant	-	NC_000012.12:g.68835842G>C	TOPMed,gnomAD
rs1365155028	p.Gly227Cys	missense variant	-	NC_000012.12:g.68835841G>T	gnomAD
rs751419968	p.Ser232Ala	missense variant	-	NC_000012.12:g.68835856T>G	ExAC,gnomAD
rs1375531162	p.Leu236Met	missense variant	-	NC_000012.12:g.68835868T>A	TOPMed
rs1334092635	p.Asp239His	missense variant	-	NC_000012.12:g.68835877G>C	gnomAD
rs549965230	p.Asp255Asn	missense variant	-	NC_000012.12:g.68835925G>A	1000Genomes,ExAC,gnomAD
rs549965230	p.Asp255His	missense variant	-	NC_000012.12:g.68835925G>C	1000Genomes,ExAC,gnomAD
rs1436736107	p.Leu261Phe	missense variant	-	NC_000012.12:g.68835943C>T	gnomAD
rs779345987	p.Glu263Asp	missense variant	-	NC_000012.12:g.68835951A>C	ExAC,gnomAD
rs568134347	p.Glu264Asp	missense variant	-	NC_000012.12:g.68835954A>C	1000Genomes
rs1254586249	p.Gln266Glu	missense variant	-	NC_000012.12:g.68835958C>G	TOPMed
rs1386405599	p.Glu267Lys	missense variant	-	NC_000012.12:g.68835961G>A	gnomAD
rs371801914	p.Glu267Ala	missense variant	-	NC_000012.12:g.68835962A>C	ESP,ExAC,TOPMed,gnomAD
rs1162032400	p.Leu268Phe	missense variant	-	NC_000012.12:g.68835964C>T	gnomAD
rs1385029841	p.Leu268Pro	missense variant	-	NC_000012.12:g.68835965T>C	gnomAD
rs1300121209	p.Asp270Glu	missense variant	-	NC_000012.12:g.68835972T>A	TOPMed,gnomAD
rs371657669	p.Val275Leu	missense variant	-	NC_000012.12:g.68836672G>T	ESP,TOPMed,gnomAD
rs373451300	p.Gln282His	missense variant	-	NC_000012.12:g.68836695G>C	ESP,ExAC,TOPMed,gnomAD
rs758860429	p.Ala283Thr	missense variant	-	NC_000012.12:g.68836696G>A	ExAC,TOPMed,gnomAD
rs1286851604	p.Ser290Ala	missense variant	-	NC_000012.12:g.68836717T>G	gnomAD
rs755429424	p.Ser298Pro	missense variant	-	NC_000012.12:g.68836741T>C	ExAC,TOPMed,gnomAD
rs547696481	p.Leu299Val	missense variant	-	NC_000012.12:g.68836744T>G	1000Genomes,ExAC,gnomAD
rs748459725	p.Asp301Gly	missense variant	-	NC_000012.12:g.68839275A>G	ExAC,gnomAD
rs1161921915	p.Cys308Tyr	missense variant	-	NC_000012.12:g.68839296G>A	TOPMed
rs778582378	p.Glu310Asp	missense variant	-	NC_000012.12:g.68839303A>C	ExAC,gnomAD
rs1353702185	p.Pro313Arg	missense variant	-	NC_000012.12:g.68839311C>G	gnomAD
rs577942747	p.Pro313Ser	missense variant	-	NC_000012.12:g.68839310C>T	1000Genomes,ExAC,TOPMed,gnomAD
rs577942747	p.Pro313Thr	missense variant	-	NC_000012.12:g.68839310C>A	1000Genomes,ExAC,TOPMed,gnomAD
rs1247132124	p.Pro314Ser	missense variant	-	NC_000012.12:g.68839313C>T	gnomAD
rs78419579	p.Leu315Val	missense variant	-	NC_000012.12:g.68839316C>G	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs78419579	p.Leu315Phe	missense variant	-	NC_000012.12:g.68839316C>T	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs867680779	p.Pro316Leu	missense variant	-	NC_000012.12:g.68839320C>T	-
rs1221150148	p.Pro316Ser	missense variant	-	NC_000012.12:g.68839319C>T	gnomAD
rs776440409	p.Asn320Asp	missense variant	-	NC_000012.12:g.68839331A>G	ExAC,gnomAD
rs372778876	p.Arg321Lys	missense variant	-	NC_000012.12:g.68839335G>A	ESP,ExAC,TOPMed,gnomAD
rs764918809	p.Cys322Arg	missense variant	-	NC_000012.12:g.68839337T>C	ExAC,gnomAD
rs1165217954	p.Trp323Cys	missense variant	-	NC_000012.12:g.68839342G>T	gnomAD
rs1451286579	p.Leu325Arg	missense variant	-	NC_000012.12:g.68839347T>G	TOPMed
rs773519801	p.Arg326Cys	missense variant	-	NC_000012.12:g.68839349C>T	ExAC,gnomAD
rs763077439	p.Arg326His	missense variant	-	NC_000012.12:g.68839350G>A	ExAC,TOPMed,gnomAD
rs377647994	p.Glu327Asp	missense variant	-	NC_000012.12:g.68839354G>T	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs760127492	p.Asp333Ala	missense variant	-	NC_000012.12:g.68839371A>C	ExAC,gnomAD
rs1454005555	p.Asp333Glu	missense variant	-	NC_000012.12:g.68839372T>G	gnomAD
rs1317562896	p.Gly335Arg	missense variant	-	NC_000012.12:g.68839376G>C	gnomAD
rs1250840344	p.Glu340Asp	missense variant	-	NC_000012.12:g.68839393A>C	gnomAD
rs768100456	p.Ile341Val	missense variant	-	NC_000012.12:g.68839394A>G	ExAC,TOPMed,gnomAD
rs187882006	p.Ile341Asn	missense variant	-	NC_000012.12:g.68839395T>A	1000Genomes
rs753138941	p.Lys344Arg	missense variant	-	NC_000012.12:g.68839404A>G	ExAC,TOPMed,gnomAD
rs777969898	p.Ala345Asp	missense variant	-	NC_000012.12:g.68839407C>A	ExAC,gnomAD
rs777969898	p.Ala345Gly	missense variant	-	NC_000012.12:g.68839407C>G	ExAC,gnomAD
rs1360489429	p.Ala345Thr	missense variant	-	NC_000012.12:g.68839406G>A	TOPMed
rs1237701932	p.Glu348Gly	missense variant	-	NC_000012.12:g.68839416A>G	TOPMed,gnomAD
rs757975502	p.Ser350Ala	missense variant	-	NC_000012.12:g.68839421T>G	ExAC,gnomAD
rs542860790	p.Thr351Lys	missense variant	-	NC_000012.12:g.68839425C>A	1000Genomes,ExAC,gnomAD
rs542860790	p.Thr351Ile	missense variant	-	NC_000012.12:g.68839425C>T	1000Genomes,ExAC,gnomAD
rs1472333807	p.Val359Leu	missense variant	-	NC_000012.12:g.68839448G>C	gnomAD
rs1421160509	p.Thr365Ala	missense variant	-	NC_000012.12:g.68839466A>G	gnomAD
rs1407906280	p.Thr365Ile	missense variant	-	NC_000012.12:g.68839467C>T	TOPMed,gnomAD
rs996214975	p.Ile366Thr	missense variant	-	NC_000012.12:g.68839470T>C	TOPMed
rs562818818	p.Ile366Val	missense variant	-	NC_000012.12:g.68839469A>G	1000Genomes,ExAC,TOPMed,gnomAD
rs562818818	p.Ile366Leu	missense variant	-	NC_000012.12:g.68839469A>T	1000Genomes,ExAC,TOPMed,gnomAD
rs553794444	p.Asn368Ser	missense variant	-	NC_000012.12:g.68839476A>G	ExAC,TOPMed,gnomAD
rs1470551216	p.Asp369Gly	missense variant	-	NC_000012.12:g.68839479A>G	gnomAD
rs1408066737	p.Arg371Thr	missense variant	-	NC_000012.12:g.68839485G>C	TOPMed
rs1381283438	p.Glu377Ala	missense variant	-	NC_000012.12:g.68839503A>C	gnomAD
rs769693191	p.Asp379Asn	missense variant	-	NC_000012.12:g.68839508G>A	ExAC,gnomAD
rs772867033	p.Ala385Pro	missense variant	-	NC_000012.12:g.68839526G>C	ExAC,gnomAD
rs763246240	p.Gln387Glu	missense variant	-	NC_000012.12:g.68839532C>G	ExAC,gnomAD
rs1476086953	p.Glu390Gly	missense variant	-	NC_000012.12:g.68839542A>G	TOPMed
rs377036953	p.Ser391Asn	missense variant	-	NC_000012.12:g.68839545G>A	1000Genomes,ExAC,gnomAD
rs759644422	p.Ser391Arg	missense variant	-	NC_000012.12:g.68839546T>G	ExAC,gnomAD
rs1261148726	p.Asp393Gly	missense variant	-	NC_000012.12:g.68839551A>G	TOPMed,gnomAD
rs767686947	p.Asp393His	missense variant	-	NC_000012.12:g.68839550G>C	ExAC,gnomAD
rs1261148726	p.Asp393Val	missense variant	-	NC_000012.12:g.68839551A>T	TOPMed,gnomAD
rs753298202	p.Tyr394Cys	missense variant	-	NC_000012.12:g.68839554A>G	ExAC,TOPMed,gnomAD
rs1293117772	p.Ser395Phe	missense variant	-	NC_000012.12:g.68839557C>T	TOPMed,gnomAD
rs1293580721	p.Thr399Ala	missense variant	-	NC_000012.12:g.68839568A>G	TOPMed
rs570992498	p.Ser401Gly	missense variant	-	NC_000012.12:g.68839574A>G	1000Genomes,ExAC,gnomAD
rs1173684536	p.Ser402Gly	missense variant	-	NC_000012.12:g.68839577A>G	gnomAD
rs367597251	p.Tyr405Cys	missense variant	-	NC_000012.12:g.68839587A>G	ESP,ExAC,TOPMed,gnomAD
rs754521846	p.Ser406Ile	missense variant	-	NC_000012.12:g.68839590G>T	ExAC,TOPMed,gnomAD
rs1347318671	p.Ser407Asn	missense variant	-	NC_000012.12:g.68839593G>A	gnomAD
rs780673045	p.Ser407Gly	missense variant	-	NC_000012.12:g.68839592A>G	ExAC,gnomAD
rs201788800	p.Gln408Leu	missense variant	-	NC_000012.12:g.68839596A>T	ESP,ExAC,TOPMed,gnomAD
rs201686188	p.Gln408His	missense variant	-	NC_000012.12:g.68839597A>C	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs1404470503	p.Val411Leu	missense variant	-	NC_000012.12:g.68839604G>T	TOPMed
rs200828111	p.Glu413Gly	missense variant	-	NC_000012.12:g.68839611A>G	1000Genomes
rs200081348	p.Phe414Ser	missense variant	-	NC_000012.12:g.68839614T>C	1000Genomes
rs771210713	p.Glu415Gly	missense variant	-	NC_000012.12:g.68839617A>G	ExAC,gnomAD
rs1225427397	p.Glu415Lys	missense variant	-	NC_000012.12:g.68839616G>A	gnomAD
rs1292651740	p.Glu417Gln	missense variant	-	NC_000012.12:g.68839622G>C	TOPMed,gnomAD
rs774767562	p.Asp421Glu	missense variant	-	NC_000012.12:g.68839636C>G	ExAC,gnomAD
rs774767562	p.Asp421Glu	missense variant	-	NC_000012.12:g.68839636C>A	ExAC,gnomAD
rs1205651053	p.Glu424Gln	missense variant	-	NC_000012.12:g.68839643G>C	gnomAD
rs1286039833	p.Glu424Val	missense variant	-	NC_000012.12:g.68839644A>T	gnomAD
rs1215689092	p.Ser425Asn	missense variant	-	NC_000012.12:g.68839647G>A	gnomAD
rs1445090126	p.Ser425Cys	missense variant	-	NC_000012.12:g.68839646A>T	gnomAD
rs1269114698	p.Ser428Cys	missense variant	-	NC_000012.12:g.68839656C>G	gnomAD
rs1376586613	p.Ser429Arg	missense variant	-	NC_000012.12:g.68839660T>G	TOPMed,gnomAD
rs747786956	p.Ser429Arg	missense variant	-	NC_000012.12:g.68839658A>C	ExAC,TOPMed,gnomAD
rs775699841	p.Ser429Asn	missense variant	-	NC_000012.12:g.68839659G>A	ExAC,gnomAD
rs761259297	p.Pro431Ser	missense variant	-	NC_000012.12:g.68839664C>T	ExAC,TOPMed,gnomAD
rs764465968	p.Leu432Phe	missense variant	-	NC_000012.12:g.68839667C>T	ExAC,gnomAD
rs777075587	p.Ile435Val	missense variant	-	NC_000012.12:g.68839676A>G	ExAC,gnomAD
rs762132706	p.Ile435Met	missense variant	-	NC_000012.12:g.68839678T>G	ExAC,gnomAD
rs765555199	p.Cys438Tyr	missense variant	-	NC_000012.12:g.68839686G>A	ExAC,gnomAD
rs1475420873	p.Gly453Asp	missense variant	-	NC_000012.12:g.68839731G>A	gnomAD
rs993369688	p.Lys454Arg	missense variant	-	NC_000012.12:g.68839734A>G	TOPMed
rs767024509	p.Met459Ile	missense variant	-	NC_000012.12:g.68839750G>C	ExAC,gnomAD
rs756110138	p.Thr463Ser	missense variant	-	NC_000012.12:g.68839760A>T	ExAC,TOPMed,gnomAD
rs1183456367	p.Lys466Gln	missense variant	-	NC_000012.12:g.68839769A>C	gnomAD
rs1044633873	p.Asn472His	missense variant	-	NC_000012.12:g.68839787A>C	TOPMed,gnomAD
rs550783815	p.Cys475Ser	missense variant	-	NC_000012.12:g.68839797G>C	1000Genomes
rs777525974	p.Val477Leu	missense variant	-	NC_000012.12:g.68839802G>T	ExAC,gnomAD
rs1183412415	p.Gln483Glu	missense variant	-	NC_000012.12:g.68839820C>G	gnomAD

Disease or phenotype associated information

Disease ID	Disease Name	Disease Type	Source
C0001418	Adenocarcinoma	group	BEFREE;LHGDN
C0001430	Adenoma	group	BEFREE
C0001486	Adenovirus Infections	group	BEFREE
C0001618	Tumors of Adrenal Cortex	group	HPO
C0002395	Alzheimer's Disease	disease	BEFREE
C0003850	Arteriosclerosis	disease	BEFREE
C0003857	Congenital arteriovenous malformation	disease	BEFREE
C0003873	Rheumatoid Arthritis	disease	BEFREE;LHGDN
C0004114	Astrocytoma	disease	BEFREE
C0004135	Ataxia Telangiectasia	disease	BEFREE
C0004153	Atherosclerosis	disease	BEFREE
C0004277	Tooth Attrition	phenotype	BEFREE
C0004364	Autoimmune Diseases	group	BEFREE
C0004763	Barrett Esophagus	disease	BEFREE
C0005684	Malignant neoplasm of urinary bladder	disease	BEFREE
C0005695	Bladder Neoplasm	group	BEFREE;LHGDN
C0005699	Blast Phase	disease	BEFREE
C0005859	Bloom Syndrome	disease	BEFREE
C0005967	Bone neoplasms	group	BEFREE
C0006118	Brain Neoplasms	group	BEFREE
C0006142	Malignant neoplasm of breast	disease	BEFREE;CTD_human
C0006413	Burkitt Lymphoma	disease	BEFREE
C0006826	Malignant Neoplasms	group	BEFREE;CGI
C0007102	Malignant tumor of colon	disease	BEFREE
C0007103	Malignant neoplasm of endometrium	disease	BEFREE
C0007107	Malignant neoplasm of larynx	disease	BEFREE
C0007112	Adenocarcinoma of prostate	disease	BEFREE
C0007114	Malignant neoplasm of skin	disease	BEFREE;HPO
C0007115	Malignant neoplasm of thyroid	disease	BEFREE
C0007121	Bronchogenic Carcinoma	disease	BEFREE
C0007129	Merkel cell carcinoma	disease	BEFREE
C0007130	Mucinous Adenocarcinoma	disease	BEFREE
C0007131	Non-Small Cell Lung Carcinoma	disease	BEFREE;CTD_human
C0007133	Carcinoma, Papillary	disease	BEFREE
C0007134	Renal Cell Carcinoma	disease	BEFREE;LHGDN
C0007137	Squamous cell carcinoma	disease	BEFREE;LHGDN
C0007138	Carcinoma, Transitional Cell	disease	BEFREE;LHGDN
C0007140	Carcinosarcoma	disease	BEFREE;LHGDN
C0007222	Cardiovascular Diseases	group	BEFREE
C0007621	Neoplastic Cell Transformation	phenotype	CTD_human
C0007787	Transient Ischemic Attack	disease	RGD
C0007847	Malignant tumor of cervix	disease	BEFREE
C0008497	Choriocarcinoma	disease	BEFREE
C0008626	Congenital chromosomal disease	group	BEFREE
C0009324	Ulcerative Colitis	disease	BEFREE
C0009375	Colonic Neoplasms	group	BEFREE;HPO;LHGDN
C0009402	Colorectal Carcinoma	disease	BEFREE
C0009404	Colorectal Neoplasms	group	BEFREE;LHGDN
C0010606	Adenoid Cystic Carcinoma	disease	BEFREE
C0011847	Diabetes	disease	BEFREE
C0011849	Diabetes Mellitus	group	BEFREE
C0014170	Endometrial Neoplasms	group	LHGDN
C0014474	Ependymoma	disease	BEFREE
C0014556	Epilepsy, Temporal Lobe	disease	LHGDN
C0014859	Esophageal Neoplasms	group	BEFREE
C0016034	Breast Fibrocystic Disease	disease	BEFREE
C0016057	Fibrosarcoma	disease	BEFREE
C0017154	Gastritis, Atrophic	disease	BEFREE
C0017168	Gastroesophageal reflux disease	disease	BEFREE
C0017525	Giant Cell Tumors	group	BEFREE
C0017636	Glioblastoma	disease	BEFREE;LHGDN
C0017638	Glioma	disease	BEFREE;CGI;LHGDN
C0018552	Hamartoma	group	BEFREE
C0018922	hemangiopericytoma	disease	BEFREE
C0018923	Hemangiosarcoma	disease	BEFREE
C0018995	Hemochromatosis	disease	BEFREE
C0019158	Hepatitis	disease	BEFREE
C0019159	Hepatitis A	disease	BEFREE
C0019163	Hepatitis B	disease	BEFREE
C0019189	Hepatitis, Chronic	disease	BEFREE
C0019348	Herpes Simplex Infections	group	BEFREE
C0019372	Herpesviridae Infections	group	BEFREE
C0019693	HIV Infections	group	BEFREE;CTD_human
C0019829	Hodgkin Disease	disease	BEFREE;LHGDN
C0020757	Ichthyoses	disease	RGD
C0021364	Male infertility	disease	BEFREE;CTD_human
C0021775	Intermittent Claudication	phenotype	RGD
C0022660	Kidney Failure, Acute	disease	BEFREE
C0023267	Fibroid Tumor	group	BEFREE
C0023269	leiomyosarcoma	disease	BEFREE;LHGDN
C0023418	leukemia	disease	BEFREE;LHGDN
C0023434	Chronic Lymphocytic Leukemia	disease	BEFREE;LHGDN
C0023449	Acute lymphocytic leukemia	disease	BEFREE
C0023452	Childhood Acute Lymphoblastic Leukemia	disease	BEFREE
C0023467	Leukemia, Myelocytic, Acute	disease	BEFREE
C0023470	Myeloid Leukemia	disease	BEFREE
C0023473	Myeloid Leukemia, Chronic	disease	BEFREE
C0023479	Acute myelomonocytic leukemia	disease	BEFREE
C0023484	Leukemia, Plasma Cell	disease	BEFREE
C0023492	Leukemia, T-Cell	disease	BEFREE
C0023493	Adult T-Cell Lymphoma/Leukemia	disease	BEFREE
C0023530	Leukopenia	disease	BEFREE
C0023531	Leukoplakia	disease	BEFREE
C0023798	Lipoma	disease	BEFREE
C0023827	liposarcoma	disease	BEFREE;LHGDN
C0023890	Liver Cirrhosis	disease	BEFREE
C0023891	Liver Cirrhosis, Alcoholic	disease	BEFREE
C0023895	Liver diseases	group	RGD
C0023903	Liver neoplasms	group	BEFREE
C0024121	Lung Neoplasms	group	BEFREE;LHGDN
C0024299	Lymphoma	group	BEFREE;HPO;LHGDN
C0024301	Lymphoma, Follicular	disease	BEFREE
C0024305	Lymphoma, Non-Hodgkin	disease	BEFREE
C0024623	Malignant neoplasm of stomach	disease	BEFREE
C0025149	Medulloblastoma	disease	BEFREE
C0025202	melanoma	disease	BEFREE;CTD_human
C0025286	Meningioma	disease	BEFREE
C0025500	Mesothelioma	disease	BEFREE
C0026277	Mixed Salivary Gland Tumor	disease	BEFREE;LHGDN
C0026764	Multiple Myeloma	disease	BEFREE
C0027022	Myeloproliferative disease	group	BEFREE
C0027051	Myocardial Infarction	disease	BEFREE
C0027070	Myoepithelioma	disease	BEFREE
C0027627	Neoplasm Metastasis	phenotype	BEFREE;LHGDN
C0027651	Neoplasms	group	BEFREE
C0027656	Neoplasms, Connective Tissue	group	BEFREE
C0027766	Nervous System Neoplasms	group	HPO
C0027809	Neurilemmoma	disease	BEFREE
C0027819	Neuroblastoma	group	BEFREE
C0027830	neurofibroma	disease	BEFREE
C0027832	Neurofibromatosis 2	disease	BEFREE
C0027859	Acoustic Neuroma	disease	BEFREE
C0027947	Neutropenia	disease	BEFREE
C0027960	Nevus	disease	BEFREE
C0027962	Melanocytic nevus	disease	BEFREE
C0028945	oligodendroglioma	disease	BEFREE
C0029408	Degenerative polyarthritis	disease	BEFREE
C0029463	Osteosarcoma	disease	BEFREE;HPO
C0029925	Ovarian Carcinoma	disease	BEFREE
C0030297	Pancreatic Neoplasm	disease	BEFREE;HPO;LHGDN
C0030305	Pancreatitis	disease	RGD
C0030354	Papilloma	disease	BEFREE
C0030521	Parathyroid Neoplasms	group	BEFREE
C0031511	Pheochromocytoma	disease	BEFREE
C0032463	Polycythemia Vera	disease	BEFREE
C0032580	Adenomatous Polyposis Coli	disease	BEFREE
C0032584	polyps	phenotype	BEFREE
C0032927	Precancerous Conditions	group	BEFREE;CTD_human
C0033036	Atrial Premature Complexes	disease	BEFREE
C0033117	Priapism	disease	RGD
C0033578	Prostatic Neoplasms	group	BEFREE;CTD_human;LHGDN
C0035305	Retinal Detachment	disease	BEFREE
C0035335	Retinoblastoma	disease	BEFREE
C0035412	Rhabdomyosarcoma	disease	BEFREE;LHGDN
C0035436	Rheumatic Fever	disease	BEFREE
C0036095	Salivary Gland Neoplasms	group	LHGDN
C0036220	Kaposi Sarcoma	disease	BEFREE
C0036341	Schizophrenia	disease	BEFREE
C0036572	Seizures	phenotype	BEFREE
C0036631	Seminoma	disease	BEFREE
C0036920	Sezary Syndrome	disease	BEFREE
C0037286	Skin Neoplasms	group	HPO
C0037579	Soft Tissue Neoplasms	group	BEFREE
C0038356	Stomach Neoplasms	group	BEFREE;LHGDN
C0038436	Post-Traumatic Stress Disorder	disease	RGD
C0039101	synovial sarcoma	disease	BEFREE;LHGDN
C0039103	Synovitis	disease	BEFREE
C0039483	Giant Cell Arteritis	disease	BEFREE
C0040028	Thrombocythemia, Essential	disease	BEFREE
C0040136	Thyroid Neoplasm	disease	BEFREE;LHGDN
C0041107	Trisomy	group	BEFREE
C0042133	Uterine Fibroids	group	BEFREE
C0042769	Virus Diseases	group	BEFREE
C0042900	Vitiligo	disease	BEFREE
C0043037	Common wart	disease	BEFREE
C0043345	Xeroderma	disease	RGD
C0079588	Ichthyosis, X-Linked	disease	BEFREE
C0079731	B-Cell Lymphomas	group	BEFREE;LHGDN
C0079744	Diffuse Large B-Cell Lymphoma	disease	BEFREE
C0079747	Low Grade Lymphoma (neoplasm)	disease	BEFREE
C0079773	Lymphoma, T-Cell, Cutaneous	disease	BEFREE
C0085390	Li-Fraumeni Syndrome	disease	BEFREE;LHGDN;ORPHANET
C0085669	Acute leukemia	disease	BEFREE
C0149678	Epstein-Barr Virus Infections	group	BEFREE
C0149782	Squamous cell carcinoma of lung	disease	BEFREE
C0151546	Oral Cavity Carcinoma	disease	BEFREE
C0151779	Cutaneous Melanoma	disease	BEFREE
C0151811	Subcutaneous nodule	phenotype	HPO
C0152013	Adenocarcinoma of lung (disorder)	disease	BEFREE
C0152018	Esophageal carcinoma	disease	BEFREE
C0153381	Malignant neoplasm of mouth	disease	BEFREE
C0153382	Malignant neoplasm of oropharynx	disease	BEFREE
C0153594	Malignant neoplasm of testis	disease	BEFREE
C0153633	Malignant neoplasm of brain	disease	BEFREE
C0153676	Secondary malignant neoplasm of lung	disease	BEFREE
C0155728	Other specified transient cerebral ischemias	disease	RGD
C0178874	Tumor Progression	phenotype	BEFREE
C0205823	Pleomorphic Lipoma	disease	BEFREE
C0205824	Liposarcoma, Dedifferentiated	disease	BEFREE;ORPHANET
C0205825	Liposarcoma, Pleomorphic	disease	BEFREE
C0205851	Germ cell tumor	group	BEFREE
C0205945	Sarcoma, Spindle Cell	disease	BEFREE
C0206624	Hepatoblastoma	disease	BEFREE
C0206627	Mixed Tumor, Mullerian	disease	BEFREE
C0206631	Lipomatous neoplasm	disease	BEFREE
C0206634	Liposarcoma, Myxoid	disease	BEFREE
C0206640	Ossifying Fibroma	disease	BEFREE
C0206642	Parosteal Osteosarcoma	disease	BEFREE
C0206655	Alveolar rhabdomyosarcoma	disease	BEFREE
C0206656	Embryonal Rhabdomyosarcoma	disease	BEFREE;LHGDN
C0206659	Embryonal Carcinoma	disease	BEFREE
C0206681	Adenocarcinoma, Clear Cell	disease	BEFREE
C0206693	Medullary carcinoma	disease	BEFREE
C0206698	Cholangiocarcinoma	disease	BEFREE
C0206706	Verrucous carcinoma	disease	LHGDN
C0206715	Neoplasms, Neuroepithelial	group	BEFREE
C0206726	gliosarcoma	disease	BEFREE
C0206727	Nerve Sheath Tumors	group	BEFREE
C0206731	Angiofibroma	disease	BEFREE;LHGDN
C0206743	Rhabdoid Tumor	disease	BEFREE
C0220611	Childhood Rhabdomyosarcoma	disease	BEFREE
C0220613	Adult Soft Tissue Sarcoma	disease	BEFREE
C0220615	Adult Acute Myeloblastic Leukemia	disease	BEFREE
C0220620	Gastrointestinal Carcinoid Tumor	disease	BEFREE
C0220621	Childhood Acute Myeloid Leukemia	disease	BEFREE
C0220633	Uveal melanoma	disease	BEFREE
C0220641	Lip and Oral Cavity Carcinoma	disease	BEFREE
C0231341	Premature aging syndrome	disease	BEFREE
C0235272	Retinal damage	phenotype	BEFREE
C0235974	Pancreatic carcinoma	disease	BEFREE
C0238152	Cardiac Sarcoma	disease	BEFREE
C0238198	Gastrointestinal Stromal Tumors	group	BEFREE
C0238462	Medullary carcinoma of thyroid	disease	BEFREE
C0238463	Papillary thyroid carcinoma	disease	BEFREE
C0242379	Malignant neoplasm of lung	disease	BEFREE
C0242383	Age related macular degeneration	disease	BEFREE
C0242647	Mucosa-Associated Lymphoid Tissue Lymphoma	disease	BEFREE
C0242852	Proliferative vitreoretinopathy	disease	BEFREE
C0259779	Fibrous Dysplasia	disease	BEFREE
C0260037	Multiple tumors	phenotype	BEFREE
C0264490	Acute respiratory failure	disease	BEFREE
C0268238	Triglyceride storage disease with ichthyosis	disease	BEFREE
C0272394	Disorder of lymph node	group	BEFREE
C0278487	Stage III Breast Cancer AJCC v6	disease	BEFREE
C0278488	Carcinoma breast stage IV	disease	BEFREE
C0278504	Non-small cell lung cancer stage I	disease	BEFREE
C0278512	Metastatic osteosarcoma	disease	BEFREE
C0278519	Recurrent Childhood Acute Lymphoblastic Leukemia	disease	BEFREE
C0278694	Disseminated neuroblastoma	disease	BEFREE
C0278704	Malignant Childhood Neoplasm	group	BEFREE
C0278876	Adult Medulloblastoma	disease	BEFREE
C0278883	Metastatic melanoma	disease	BEFREE
C0278996	Malignant Head and Neck Neoplasm	disease	BEFREE
C0279000	Liver and Intrahepatic Biliary Tract Carcinoma	disease	BEFREE
C0279084	Kaposi's sarcoma classical type	disease	BEFREE
C0279626	Squamous cell carcinoma of esophagus	disease	BEFREE
C0279628	Adenocarcinoma Of Esophagus	disease	BEFREE
C0279702	Conventional (Clear Cell) Renal Cell Carcinoma	disease	BEFREE
C0280100	Solid Neoplasm	phenotype	BEFREE
C0280217	stage, non-small cell lung cancer	disease	BEFREE
C0280220	stage, ovarian epithelial cancer	disease	BEFREE
C0280324	Laryngeal Squamous Cell Carcinoma	disease	BEFREE
C0280631	Leiomyosarcoma of uterus	disease	BEFREE
C0281361	Adenocarcinoma of pancreas	disease	BEFREE
C0282313	Condition, Preneoplastic	phenotype	CTD_human
C0302592	Cervix carcinoma	disease	BEFREE
C0334121	Inflammatory Myofibroblastic Tumor	disease	BEFREE
C0334279	Adenocarcinoma, intestinal type	disease	BEFREE
C0334424	Nodular melanoma	disease	BEFREE
C0334463	Malignant Fibrous Histiocytoma	disease	BEFREE
C0334474	Spindle cell lipoma	disease	BEFREE
C0334579	Anaplastic astrocytoma	disease	BEFREE
C0334590	Anaplastic Oligodendroglioma	disease	BEFREE
C0334634	Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse	disease	BEFREE;LHGDN
C0343641	Human papilloma virus infection	disease	BEFREE
C0344460	Carcinoma ex pleomorphic adenoma	disease	BEFREE
C0345904	Malignant neoplasm of liver	disease	BEFREE
C0345905	Intrahepatic Cholangiocarcinoma	disease	BEFREE
C0345967	Malignant mesothelioma	disease	BEFREE
C0346153	Breast Cancer, Familial	disease	BEFREE
C0346647	Malignant neoplasm of pancreas	disease	BEFREE;HPO
C0347206	Benign tumor of salivary gland	disease	BEFREE
C0349534	Carcinoma of anal margin	disease	BEFREE
C0376358	Malignant neoplasm of prostate	disease	BEFREE;CTD_human
C0376545	Hematologic Neoplasms	group	BEFREE
C0392784	Dermatofibrosarcoma Protuberans	disease	BEFREE
C0398791	Nijmegen Breakage Syndrome	disease	BEFREE
C0424295	Hyperactive behavior	phenotype	BEFREE
C0457522	Juvenile ossifying fibroma	disease	BEFREE
C0476089	Endometrial Carcinoma	disease	BEFREE
C0494165	Secondary malignant neoplasm of liver	disease	BEFREE
C0496779	Malignant neoplasm of appendix	disease	BEFREE
C0496836	Malignant tumor of eye	disease	BEFREE
C0497550	Benign neurologic neoplasms	group	BEFREE
C0520463	Chronic active hepatitis	disease	BEFREE
C0524909	Hepatitis B, Chronic	disease	BEFREE
C0524910	Hepatitis C, Chronic	disease	BEFREE;LHGDN
C0545074	Myxoid/Round Cell Liposarcoma	disease	BEFREE
C0545080	Composite Lymphoma	disease	BEFREE
C0546837	Malignant neoplasm of esophagus	disease	BEFREE
C0549473	Thyroid carcinoma	disease	BEFREE
C0553580	Ewings sarcoma	disease	BEFREE
C0555198	Malignant Glioma	disease	BEFREE
C0585442	Osteosarcoma of bone	disease	BEFREE
C0595989	Carcinoma of larynx	disease	BEFREE
C0596263	Carcinogenesis	phenotype	BEFREE
C0598766	Leukemogenesis	disease	BEFREE
C0598935	Tumor Initiation	phenotype	BEFREE
C0600139	Prostate carcinoma	disease	BEFREE
C0677483	Carcinoma testes	disease	BEFREE
C0677886	Epithelial ovarian cancer	disease	BEFREE
C0677898	invasive cancer	phenotype	BEFREE
C0677932	Progressive Neoplastic Disease	phenotype	BEFREE
C0678222	Breast Carcinoma	disease	BEFREE;CTD_human;HPO
C0684249	Carcinoma of lung	disease	BEFREE
C0684337	Ewings sarcoma-primitive neuroectodermal tumor (PNET)	disease	BEFREE
C0686619	Secondary malignant neoplasm of lymph node	disease	BEFREE
C0699790	Colon Carcinoma	disease	BEFREE
C0699791	Stomach Carcinoma	disease	BEFREE
C0699885	Carcinoma of bladder	disease	BEFREE
C0699893	Skin carcinoma	disease	BEFREE;HPO
C0700095	Central neuroblastoma	disease	BEFREE
C0700636	Focal nodular hyperplasia of liver	disease	BEFREE
C0740457	Malignant neoplasm of kidney	disease	BEFREE
C0740479	Undifferentiated High Grade Pleomorphic Sarcoma of Bone	disease	BEFREE
C0741682	Premenopausal breast cancer	disease	BEFREE
C0745730	Multiple lipomata	disease	GENOMICS_ENGLAND
C0746883	Febrile Neutropenia	disease	BEFREE
C0746926	Multiple, subcutaneous nodules	disease	HPO
C0747845	early pregnancy	phenotype	BEFREE
C0750974	Brain Tumor, Primary	disease	BEFREE
C0751396	Well Differentiated Oligodendroglioma	disease	BEFREE
C0751483	Familial Retinoblastoma	disease	BEFREE
C0751606	Adult Acute Lymphocytic Leukemia	disease	BEFREE
C0751688	Malignant Squamous Cell Neoplasm	disease	BEFREE
C0751690	Malignant Peripheral Nerve Sheath Tumor	disease	BEFREE
C0796563	Localized Malignant Neoplasm	phenotype	BEFREE
C0812413	Malignant Pleural Mesothelioma	disease	BEFREE
C0848676	Subfertility, Male	phenotype	CTD_human
C0850666	Infection caused by Helicobacter pylori	disease	BEFREE
C0853879	Invasive carcinoma of breast	disease	BEFREE
C0854778	Pancreatic carcinoma resectable	disease	BEFREE
C0854915	Retinoblastoma unilateral	disease	BEFREE
C0855073	Undifferentiated (Embryonal) Sarcoma	disease	BEFREE
C0855197	Malignant Testicular Germ Cell Tumor	disease	BEFREE
C0858252	Breast adenocarcinoma	disease	BEFREE
C0917731	Male sterility	phenotype	CTD_human
C0919267	ovarian neoplasm	disease	BEFREE
C0948750	Salivary gland carcinoma	disease	BEFREE
C1134719	Invasive Ductal Breast Carcinoma	disease	BEFREE
C1136033	Cutaneous Mastocytosis	disease	BEFREE
C1140680	Malignant neoplasm of ovary	disease	BEFREE
C1153706	Endometrial adenocarcinoma	disease	BEFREE
C1168401	Squamous cell carcinoma of the head and neck	disease	BEFREE
C1257931	Mammary Neoplasms, Human	group	CTD_human
C1260965	Lipoblastoma	disease	BEFREE
C1261473	Sarcoma	group	BEFREE;CGI;LHGDN
C1266129	Atypical Lipoma	disease	BEFREE
C1266157	Intratubular malignant germ cells	disease	BEFREE
C1266163	Intraosseous well differentiated osteosarcoma	disease	BEFREE
C1275122	Familial multiple trichoepitheliomata	disease	BEFREE
C1275275	Spindle cell liposarcoma	disease	BEFREE
C1292753	Primary Effusion Lymphoma	disease	BEFREE
C1292769	Precursor B-cell lymphoblastic leukemia	disease	BEFREE
C1292778	Chronic myeloproliferative disorder	disease	BEFREE
C1306050	Primary malignant neoplasm of appendix	disease	BEFREE
C1306459	Primary malignant neoplasm	group	BEFREE
C1306460	Primary malignant neoplasm of lung	disease	BEFREE
C1319315	Adenocarcinoma of large intestine	disease	BEFREE;CGI
C1332078	Anaplastic large cell lymphoma, ALK negative	disease	BEFREE
C1332850	Cardiac Lymphoma	disease	BEFREE
C1332977	Childhood Leukemia	disease	BEFREE
C1333064	Classical Hodgkin's Lymphoma	disease	BEFREE
C1333280	Desmoplastic melanoma	disease	BEFREE
C1333600	Hereditary Malignant Neoplasm	group	BEFREE
C1333762	Gastric Cardia Adenocarcinoma	disease	BEFREE
C1333763	Gastric Cardia Carcinoma	disease	BEFREE
C1333977	Hepatitis B Virus-Related Hepatocellular Carcinoma	disease	BEFREE
C1333990	Hereditary Nonpolyposis Colorectal Cancer	disease	BEFREE
C1334054	Human Papillomavirus-Related Esophageal Squamous Cell Carcinoma	disease	BEFREE
C1334170	Indolent Non-Hodgkin Lymphoma	disease	BEFREE
C1334274	Invasive Carcinoma	phenotype	BEFREE
C1334407	Localized Carcinoma	phenotype	BEFREE
C1335110	Oligodendroglial Neoplasm	disease	BEFREE
C1335302	Pancreatic Ductal Adenocarcinoma	disease	BEFREE
C1336077	Sporadic Burkitt's lymphoma	disease	BEFREE
C1336735	Treatment related acute myeloid leukaemia	disease	BEFREE
C1337013	Differentiated Thyroid Gland Carcinoma	disease	BEFREE
C1367654	Marginal Zone B-Cell Lymphoma	disease	BEFREE
C1370889	Liposarcoma, well differentiated	disease	BEFREE;ORPHANET
C1377843	Periosteal Osteosarcoma	disease	BEFREE
C1378703	Renal carcinoma	disease	BEFREE
C1412036	Anal squamous cell carcinoma	disease	BEFREE
C1449563	Cardiomyopathy, Familial Idiopathic	disease	BEFREE
C1456781	Benign melanocytic nevus	disease	BEFREE
C1458155	Mammary Neoplasms	group	BEFREE;CTD_human;LHGDN
C1512409	Hepatocarcinogenesis	disease	BEFREE
C1512981	Mammary Tumorigenesis	phenotype	BEFREE
C1514225	Poorly Differentiated Neuroblastoma	disease	BEFREE
C1517445	Ganglioneuroblastoma, Nodular	disease	BEFREE
C1519176	Salivary Gland Pleomorphic Adenoma	disease	BEFREE
C1519670	Tumor Angiogenesis	phenotype	BEFREE
C1519689	Tumor Promotion	phenotype	BEFREE
C1527249	Colorectal Cancer	disease	BEFREE
C1559154	Rash and Dermatitis Adverse Event Associated with Chemoradiation	disease	BEFREE
C1621958	Glioblastoma Multiforme	disease	BEFREE
C1623038	Cirrhosis	disease	BEFREE
C1658953	tumor vasculature	phenotype	BEFREE
C1704356	Enchondroma	disease	BEFREE
C1704423	Milroy Disease	disease	BEFREE
C1708550	Intimal sarcoma	disease	BEFREE
C1762616	Meningioma, benign, no ICD-O subtype	disease	BEFREE
C1838578	Progressive encephalopathy	phenotype	HPO
C1842408	increased risk of pancreatic cancer	phenotype	HPO
C1847835	VITILIGO-ASSOCIATED MULTIPLE AUTOIMMUNE DISEASE SUSCEPTIBILITY 1 (finding)	disease	BEFREE
C1883486	Uterine Corpus Cancer	disease	BEFREE
C1961102	Precursor Cell Lymphoblastic Leukemia Lymphoma	disease	BEFREE;LHGDN
C1969372	Tubulointerstitial fibrosis	disease	BEFREE
C2145472	Urothelial Carcinoma	disease	BEFREE
C2239176	Liver carcinoma	disease	BEFREE;LHGDN
C2349952	Oropharyngeal Carcinoma	disease	BEFREE
C2717836	Steroid Sulfatase Deficiency Disease	disease	BEFREE
C2931822	Nasopharyngeal carcinoma	disease	BEFREE
C2939420	Metastatic Neoplasm	phenotype	BEFREE
C3146271	Stage III Breast Cancer AJCC v7	disease	BEFREE
C3249875	Laryngopharyngeal Cancer	disease	BEFREE
C3280690	ACCELERATED TUMOR FORMATION, SUSCEPTIBILITY TO	phenotype	CLINVAR
C3463824	MYELODYSPLASTIC SYNDROME	group	BEFREE
C3469186	HEMOCHROMATOSIS, TYPE 1	disease	BEFREE
C3489413	Lipomatosis, Multiple	disease	BEFREE
C3539781	Progressive cGVHD	disease	BEFREE
C3539878	Triple Negative Breast Neoplasms	disease	BEFREE
C3693482	Giant Cell Fibroblastoma	disease	BEFREE
C3714514	Infection	group	LHGDN
C3714948	PACHYONYCHIA CONGENITA 3	disease	BEFREE
C3811653	Experimental Organism Basal Cell Carcinoma	phenotype	BEFREE
C3887461	Head and Neck Carcinoma	disease	BEFREE
C3888194	MIXED LINEAGE LEUKEMIA	disease	BEFREE
C4021985	Germ cell neoplasia	disease	BEFREE
C4024981	Localized neuroblastoma	disease	BEFREE
C4041089	Poorly differentiated sarcoma	disease	BEFREE
C4048297	Idiopathic retroperitoneal fibrosis	disease	BEFREE
C4048328	cervical cancer	disease	BEFREE
C4054891	Grade III Chondrosarcoma	disease	BEFREE
C4280575	Progressive brain disease	disease	HPO
C4505456	HIV Coinfection	disease	CTD_human

Gene Ontology (GO)/biological pathways

GO:Molecular Function

GO ID	GO Term	Evidence
GO:0002039	p53 binding	IPI
GO:0004842	ubiquitin-protein transferase activity	IMP
GO:0004842	ubiquitin-protein transferase activity	IDA
GO:0005515	protein binding	IPI
GO:0008097	5S rRNA binding	IDA
GO:0008270	zinc ion binding	IDA
GO:0016874	ligase activity	IDA
GO:0019789	SUMO transferase activity	EXP
GO:0019899	enzyme binding	IPI
GO:0019904	protein domain specific binding	IPI
GO:0031625	ubiquitin protein ligase binding	IPI
GO:0033612	receptor serine/threonine kinase binding	IEA
GO:0042802	identical protein binding	IPI
GO:0042975	peroxisome proliferator activated receptor binding	IEA
GO:0043021	ribonucleoprotein complex binding	IDA
GO:0043130	ubiquitin binding	IDA
GO:0047485	protein N-terminus binding	IPI
GO:0061630	ubiquitin protein ligase activity	IDA
GO:0061630	ubiquitin protein ligase activity	IMP
GO:0061630	ubiquitin protein ligase activity	TAS
GO:0061663	NEDD8 ligase activity	IMP
GO:0097110	scaffold protein binding	IEA
GO:0097718	disordered domain specific binding	IPI

GO:Biological Process

GO ID	GO Term	Evidence
GO:0000122	negative regulation of transcription by RNA polymerase II	IDA
GO:0000209	protein polyubiquitination	TAS
GO:0001568	blood vessel development	IEA
GO:0001974	blood vessel remodeling	IEA
GO:0002027	regulation of heart rate	IEA
GO:0003181	atrioventricular valve morphogenesis	IEA
GO:0003203	endocardial cushion morphogenesis	IEA
GO:0003281	ventricular septum development	IEA
GO:0003283	atrial septum development	IEA
GO:0006511	ubiquitin-dependent protein catabolic process	IDA
GO:0006511	ubiquitin-dependent protein catabolic process	IMP
GO:0006511	ubiquitin-dependent protein catabolic process	IGI
GO:0006977	DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest	IMP
GO:0006977	DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest	TAS
GO:0007089	traversing start control point of mitotic cell cycle	IEA
GO:0008284	positive regulation of cell population proliferation	TAS
GO:0010039	response to iron ion	IEA
GO:0010628	positive regulation of gene expression	IEA
GO:0010955	negative regulation of protein processing	IEA
GO:0010977	negative regulation of neuron projection development	IEA
GO:0016032	viral process	IEA
GO:0016567	protein ubiquitination	IDA
GO:0016579	protein deubiquitination	TAS
GO:0016925	protein sumoylation	IEA
GO:0018205	peptidyl-lysine modification	IMP
GO:0031648	protein destabilization	IDA
GO:0031648	protein destabilization	IMP
GO:0032026	response to magnesium ion	IEA
GO:0032436	positive regulation of proteasomal ubiquitin-dependent protein catabolic process	IDA
GO:0034504	protein localization to nucleus	IDA
GO:0036369	transcription factor catabolic process	TAS
GO:0042176	regulation of protein catabolic process	IDA
GO:0042220	response to cocaine	IEA
GO:0043154	negative regulation of cysteine-type endopeptidase activity involved in apoptotic process	IEA
GO:0043161	proteasome-mediated ubiquitin-dependent protein catabolic process	TAS
GO:0043278	response to morphine	IEA
GO:0043518	negative regulation of DNA damage response, signal transduction by p53 class mediator	IDA
GO:0045184	establishment of protein localization	IDA
GO:0045472	response to ether	IEA
GO:0045892	negative regulation of transcription, DNA-templated	IMP
GO:0045892	negative regulation of transcription, DNA-templated	IDA
GO:0045931	positive regulation of mitotic cell cycle	IMP
GO:0046677	response to antibiotic	IEP
GO:0046827	positive regulation of protein export from nucleus	IEA
GO:0048545	response to steroid hormone	IEA
GO:0051149	positive regulation of muscle cell differentiation	IEA
GO:0051603	proteolysis involved in cellular protein catabolic process	IMP
GO:0051865	protein autoubiquitination	IMP
GO:0060411	cardiac septum morphogenesis	IEA
GO:0065003	protein-containing complex assembly	IDA
GO:0070301	cellular response to hydrogen peroxide	IEA
GO:0071157	negative regulation of cell cycle arrest	IDA
GO:0071301	cellular response to vitamin B1	IEA
GO:0071312	cellular response to alkaloid	IEA
GO:0071363	cellular response to growth factor stimulus	IEA
GO:0071375	cellular response to peptide hormone stimulus	IEA
GO:0071391	cellular response to estrogen stimulus	IEA
GO:0071456	cellular response to hypoxia	IEP
GO:0071480	cellular response to gamma radiation	IDA
GO:0071494	cellular response to UV-C	IEA
GO:0072717	cellular response to actinomycin D	IDA
GO:1901796	regulation of signal transduction by p53 class mediator	TAS
GO:1901797	negative regulation of signal transduction by p53 class mediator	IDA
GO:1901797	negative regulation of signal transduction by p53 class mediator	TAS
GO:1902254	negative regulation of intrinsic apoptotic signaling pathway by p53 class mediator	IMP
GO:1904404	response to formaldehyde	IEA
GO:1904707	positive regulation of vascular smooth muscle cell proliferation	IEA
GO:1904754	positive regulation of vascular associated smooth muscle cell migration	IEA
GO:1990000	amyloid fibril formation	IMP
GO:1990785	response to water-immersion restraint stress	IEA

GO:Cellular Component

GO ID	GO Term	Evidence
GO:0005634	nucleus	IDA
GO:0005634	nucleus	IMP
GO:0005654	nucleoplasm	IDA
GO:0005654	nucleoplasm	TAS
GO:0005730	nucleolus	IDA
GO:0005730	nucleolus	IMP
GO:0005737	cytoplasm	IMP
GO:0005829	cytosol	TAS
GO:0005886	plasma membrane	TAS
GO:0030666	endocytic vesicle membrane	TAS
GO:0032991	protein-containing complex	IMP
GO:0032991	protein-containing complex	IDA
GO:0045202	synapse	IEA
GO:0016604	nuclear body	IDA

Reactome Pathway

Reactome ID	Reactome Term	Evidence
R-HSA-112314	Neurotransmitter receptors and postsynaptic signal transmission	TAS
R-HSA-112315	Transmission across Chemical Synapses	TAS
R-HSA-112316	Neuronal System	TAS
R-HSA-1257604	PIP3 activates AKT signaling	TAS
R-HSA-162582	Signal Transduction	TAS
R-HSA-1640170	Cell Cycle	TAS
R-HSA-1643685	Disease	TAS
R-HSA-198323	AKT phosphorylates targets in the cytosol	TAS
R-HSA-212436	Generic Transcription Pathway	TAS
R-HSA-2219528	PI3K/AKT Signaling in Cancer	TAS
R-HSA-2262752	Cellular responses to stress	TAS
R-HSA-2559580	Oxidative Stress Induced Senescence	TAS
R-HSA-2559583	Cellular Senescence	TAS
R-HSA-2559585	Oncogene Induced Senescence	TAS
R-HSA-2990846	SUMOylation	TAS
R-HSA-3108232	SUMO E3 ligases SUMOylate target proteins	TAS
R-HSA-3232118	SUMOylation of transcription factors	TAS
R-HSA-3232142	SUMOylation of ubiquitinylation proteins	TAS
R-HSA-3700989	Transcriptional Regulation by TP53	TAS
R-HSA-392499	Metabolism of proteins	TAS
R-HSA-399719	Trafficking of AMPA receptors	TAS
R-HSA-399721	Glutamate binding, activation of AMPA receptors and synaptic plasticity	TAS
R-HSA-5633007	Regulation of TP53 Activity	TAS
R-HSA-5663202	Diseases of signal transduction	TAS
R-HSA-5674400	Constitutive Signaling by AKT1 E17K in Cancer	TAS
R-HSA-5688426	Deubiquitination	TAS
R-HSA-5689880	Ub-specific processing proteases	TAS
R-HSA-597592	Post-translational protein modification	TAS
R-HSA-6804756	Regulation of TP53 Activity through Phosphorylation	TAS
R-HSA-6804757	Regulation of TP53 Degradation	TAS
R-HSA-6804760	Regulation of TP53 Activity through Methylation	TAS
R-HSA-6806003	Regulation of TP53 Expression and Degradation	TAS
R-HSA-69541	Stabilization of p53	TAS
R-HSA-69563	p53-Dependent G1 DNA Damage Response	TAS
R-HSA-69580	p53-Dependent G1/S DNA damage checkpoint	TAS
R-HSA-69615	G1/S DNA Damage Checkpoints	TAS
R-HSA-69620	Cell Cycle Checkpoints	TAS
R-HSA-73857	RNA Polymerase II Transcription	TAS
R-HSA-74160	Gene expression (Transcription)	TAS
R-HSA-8878159	Transcriptional regulation by RUNX3	TAS
R-HSA-8941858	Regulation of RUNX3 expression and activity	TAS
R-HSA-8953897	Cellular responses to external stimuli	TAS
R-HSA-9006925	Intracellular signaling by second messengers	TAS

Drugs and compounds information

ID	Drug Name	Action	PubMed
C028098	10-hydroxycamptothecin	MDM2 protein affects the susceptibility to 10-hydroxycamptothecin	13130078
C025205	1,10-phenanthroline	1,10-phenanthroline results in increased expression of MDM2 mRNA	19502547
C026486	1,2,5,6-dibenzanthracene	1,2,5,6-dibenzanthracene results in increased expression of MDM2 mRNA	26377693
C576882	1-(2-trifluoromethoxyphenyl)-2-nitroethanone	1-(2-trifluoromethoxyphenyl)-2-nitroethanone results in increased expression of MDM2 mRNA	25596134
C028474	1,4-bis(2-(3,5-dichloropyridyloxy))benzene	1,4-bis(2-(3,5-dichloropyridyloxy))benzene results in increased expression of MDM2 mRNA	23684557
C028474	1,4-bis(2-(3,5-dichloropyridyloxy))benzene	1,4-bis(2-(3,5-dichloropyridyloxy))benzene results in increased expression of MDM2 protein	23684557
C095284	1H-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one	1H-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one results in increased expression of MDM2 protein	16288207
C032668	1-nitropyrene	1-nitropyrene results in increased expression of MDM2 mRNA	10837373
C032668	1-nitropyrene	1-nitropyrene results in increased expression of MDM2 protein	22044530
C032668	1-nitropyrene	1-nitropyrene results in increased expression of MDM2 protein modified form	22044530
C032668	1-nitropyrene	nutlin 3 results in increased susceptibility to [1-nitropyrene results in increased expression of MDM2 protein]	22044530
C032668	1-nitropyrene	nutlin 3 results in increased susceptibility to [1-nitropyrene results in increased expression of MDM2 protein modified form]	22044530
C032668	1-nitropyrene	Tetrachlorodibenzodioxin results in decreased susceptibility to [1-nitropyrene results in increased expression of MDM2 protein]	22044530
C032668	1-nitropyrene	Tetrachlorodibenzodioxin results in decreased susceptibility to [1-nitropyrene results in increased expression of MDM2 protein modified form]	22044530
C032668	1-nitropyrene	TP53 affects the reaction [1-nitropyrene results in increased expression of MDM2 mRNA]	10837373
C541131	2,2',3,3',4,4',5-heptachlorobiphenyl	2,2',3,3',4,4',5-heptachlorobiphenyl results in increased phosphorylation of MDM2 protein	19751709
C029790	2,2',3',4,4',5-hexachlorobiphenyl	2,2',3',4,4',5-hexachlorobiphenyl results in increased phosphorylation of MDM2 protein	19751709
C032904	2,2',3,5',6-pentachlorobiphenyl	2,2',3,5',6-pentachlorobiphenyl results in increased phosphorylation of MDM2 protein	19751709
C093973	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Cadmium Chloride results in increased phosphorylation of MDM2 protein]	25744307
C093973	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [sodium arsenite results in increased expression of MDM2 protein]	28785074
C093973	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one results in decreased expression of MDM2 protein	28785074
C451219	2,2-bis(hydroxymethyl)-1-azabicyclo(2,2,2,)octan-3-one	2,2-bis(hydroxymethyl)-1-azabicyclo(2,2,2,)octan-3-one results in increased expression of MDM2	21647879
C010498	2,3,6,2',3',6'-hexachlorobiphenyl	2,3,6,2',3',6'-hexachlorobiphenyl results in increased phosphorylation of MDM2 protein	19751709
C035976	2,4,2',4'-tetrachlorobiphenyl	2,4,2',4'-tetrachlorobiphenyl results in increased phosphorylation of MDM2 protein	19751709
C541132	2,4,4',5-tetrachlorobiphenyl	2,4,4',5-tetrachlorobiphenyl results in increased phosphorylation of MDM2 protein	19751709
C081766	2,4,4'-trichlorobiphenyl	2,4,4'-trichlorobiphenyl inhibits the reaction [Benzo(a)pyrene results in increased phosphorylation of MDM2 protein]	20840854
C081766	2,4,4'-trichlorobiphenyl	2,4,4'-trichlorobiphenyl results in increased phosphorylation of MDM2 protein	19751709; 20840854;
C014024	2,4,5,2',4',5'-hexachlorobiphenyl	2,4,5,2',4',5'-hexachlorobiphenyl inhibits the reaction [Benzo(a)pyrene results in increased phosphorylation of MDM2 protein]	20840854
C014024	2,4,5,2',4',5'-hexachlorobiphenyl	2,4,5,2',4',5'-hexachlorobiphenyl results in increased phosphorylation of MDM2 protein	19751709; 20840854;
C009828	2,4,5,2',5'-pentachlorobiphenyl	2,4,5,2',5'-pentachlorobiphenyl inhibits the reaction [Benzo(a)pyrene results in increased phosphorylation of MDM2 protein]	20840854
C009828	2,4,5,2',5'-pentachlorobiphenyl	2,4,5,2',5'-pentachlorobiphenyl results in increased phosphorylation of MDM2 protein	19751709; 20840854;
C009828	2,4,5,2',5'-pentachlorobiphenyl	MDM2 mutant form inhibits the reaction [2,4,5,2',5'-pentachlorobiphenyl results in decreased phosphorylation of FOXO3 protein]	20840854
C016403	2,4-dinitrotoluene	2,4-dinitrotoluene affects the expression of MDM2 mRNA	21346803
C009407	2,5,2',5'-tetrachlorobiphenyl	2,5,2',5'-tetrachlorobiphenyl results in increased phosphorylation of MDM2 protein	19751709
C023514	2,6-dinitrotoluene	2,6-dinitrotoluene affects the expression of MDM2 mRNA	21346803
D015073	2-Acetylaminofluorene	2-Acetylaminofluorene results in increased expression of MDM2 mRNA	21607683
D015073	2-Acetylaminofluorene	2-Acetylaminofluorene results in increased expression of MDM2 mRNA	19167416; 22213190; 22584684;
D015073	2-Acetylaminofluorene	2-Acetylaminofluorene results in increased expression of MDM2 protein	19167416
D015073	2-Acetylaminofluorene	[Diethylnitrosamine co-treated with 2-Acetylaminofluorene] affects the expression of and affects the localization of MDM2 protein	11003613
C049584	2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine	2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of MDM2 protein	15635149
C546460	2-amino-3-methyl-3H-imidazo(4,5-f)quinoline	2-amino-3-methyl-3H-imidazo(4,5-f)quinoline results in decreased expression of MDM2 mRNA	23810796
C018535	2-ethylhexyldiphenylphosphate	2-ethylhexyldiphenylphosphate results in increased expression of MDM2 mRNA	30981936
C533410	2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one	[Cisplatin co-treated with 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one co-treated with Oxygen deficiency] results in increased expression of MDM2 mRNA	29690507
C533410	2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one	[Cisplatin co-treated with 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one] results in increased expression of MDM2 mRNA	29690507
C533410	2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one	[Oxygen deficiency co-treated with 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one] results in increased expression of MDM2 mRNA	29690507
C019499	2-nitrofluorene	2-nitrofluorene results in increased expression of MDM2 mRNA	14600272; 15890375; 22484513; 23052194;
C054649	3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol	3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol results in increased expression of MDM2 mRNA	12734338
C016392	3,3'-diindolylmethane	3,3'-diindolylmethane analog results in decreased expression of MDM2 mRNA	26593444
C023035	3,4,5,3',4'-pentachlorobiphenyl	3,4,5,3',4'-pentachlorobiphenyl promotes the reaction [Benzo(a)pyrene results in increased phosphorylation of MDM2 protein]	20840854
C023035	3,4,5,3',4'-pentachlorobiphenyl	3,4,5,3',4'-pentachlorobiphenyl results in increased phosphorylation of MDM2 protein	19751709; 20840854;
C023035	3,4,5,3',4'-pentachlorobiphenyl	MDM2 mutant form inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in decreased phosphorylation of FOXO3 protein]	20840854
C482492	3,4,5,4'-tetramethoxystilbene	3,4,5,4'-tetramethoxystilbene results in decreased expression of MDM2 mRNA	31170421
C045421	3,4,8-trimethylimidazo(4,5-f)quinoxalin-2-amine	3,4,8-trimethylimidazo(4,5-f)quinoxalin-2-amine results in increased expression of MDM2 mRNA	23810796
C501634	3-(4-chlorophenyl)-3-(4-hydroxy-3,5-dimethoxybenzyloxy)-2-propyl-2,3-dihydroisoindol-1-one	3-(4-chlorophenyl)-3-(4-hydroxy-3,5-dimethoxybenzyloxy)-2-propyl-2,3-dihydroisoindol-1-one results in decreased activity of [MDM2 protein binds to TP53 protein]	21314128
C472791	3-(4'-hydroxy-3'-adamantylbiphenyl-4-yl)acrylic acid	3-(4'-hydroxy-3'-adamantylbiphenyl-4-yl)acrylic acid results in increased expression of MDM2 mRNA	16788091
C009505	4,4'-diaminodiphenylmethane	4,4'-diaminodiphenylmethane results in increased expression of MDM2 mRNA	18648102
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MDM2 mRNA	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MDM2 mRNA	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MDM2 mRNA	27188386
C508085	4'-demethyldesoxypodophyllotoxin	4'-demethyldesoxypodophyllotoxin analog results in increased cleavage of MDM2 protein	25446499
C016583	4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone	4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased expression of MDM2 mRNA	14600272; 15890375; 22484513; 23052194;
C471843	6-((3-chloro)anilino)-2-(isopropyl-2-hydroxyethylamino)-9-isopropylpurine	6-((3-chloro)anilino)-2-(isopropyl-2-hydroxyethylamino)-9-isopropylpurine results in decreased expression of MDM2 protein	15958644
D015123	7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased expression of MDM2 mRNA	20382639; 26238291; 28593498;
C553817	7-(benzylamino)-1,3,4,8-tetrahydropyrrolo(4,3,2-de)quinolin-8(1H)-one	7-(benzylamino)-1,3,4,8-tetrahydropyrrolo(4,3,2-de)quinolin-8(1H)-one results in decreased expression of MDM2 protein	19936915
D015127	9,10-Dimethyl-1,2-benzanthracene	9,10-Dimethyl-1,2-benzanthracene results in increased expression of MDM2 mRNA	23717041
D015127	9,10-Dimethyl-1,2-benzanthracene	[epigallocatechin gallate co-treated with Polylactic Acid-Polyglycolic Acid Copolymer analog] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of MDM2 mRNA]	23717041
D015127	9,10-Dimethyl-1,2-benzanthracene	[theaflavin co-treated with Polylactic Acid-Polyglycolic Acid Copolymer analog] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of MDM2 mRNA]	23717041
D015127	9,10-Dimethyl-1,2-benzanthracene	theaflavin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of MDM2 mRNA]	23717041
D000082	Acetaminophen	Acetaminophen results in decreased expression of MDM2 mRNA	21420995
D000082	Acetaminophen	Acetaminophen results in increased expression of MDM2 mRNA	22230336
D000082	Acetaminophen	Acetaminophen affects the expression of MDM2 mRNA	17562736
D000082	Acetaminophen	Acetaminophen results in increased expression of MDM2 mRNA	26056430
D000082	Acetaminophen	[Clofibrate co-treated with Acetaminophen] affects the expression of MDM2 mRNA	17585979
D000082	Acetaminophen	PPARA affects the reaction [[Clofibrate co-treated with Acetaminophen] affects the expression of MDM2 mRNA]	17585979
D000082	Acetaminophen	Acetaminophen promotes the reaction [MDM2 protein binds to TP53 protein]	16330492
D000082	Acetaminophen	Acetaminophen results in decreased expression of MDM2 mRNA	21807079
D000082	Acetaminophen	Acetaminophen results in increased expression of MDM2 mRNA	17202762
D000082	Acetaminophen	Acetaminophen results in increased phosphorylation of MDM2 protein	16330492
C106812	adefovir dipivoxil	adefovir dipivoxil results in increased expression of MDM2 mRNA	25596134
D016604	Aflatoxin B1	Aflatoxin B1 affects the expression of MDM2 protein	20106945
D016604	Aflatoxin B1	Aflatoxin B1 results in decreased methylation of MDM2 gene	27153756
D016604	Aflatoxin B1	Aflatoxin B1 results in increased expression of MDM2 mRNA	21632981; 21641981; 27153756; 29445054; 31555880;
D016604	Aflatoxin B1	Aflatoxin B1 results in increased expression of MDM2 mRNA	19770486
D016604	Aflatoxin B1	Aflatoxin B1 results in increased expression of MDM2 mRNA	14600272; 15890375; 22484513; 23052194; 23630614; 25378103;
D016607	Aflatoxin M1	Aflatoxin M1 results in decreased expression of MDM2 mRNA	30928695
C011512	alpha-naphthoflavone	alpha-naphthoflavone inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [Oxygen deficiency results in increased expression of MDM2 mRNA]]	19578757
C011512	alpha-naphthoflavone	alpha-naphthoflavone inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of MDM2 mRNA]	19578757
C067527	aluminum maltolate	aluminum maltolate results in increased expression of MDM2 mRNA	15537749
C077990	alvocidib	alvocidib results in decreased expression of MDM2 mRNA	12589031
C077990	alvocidib	alvocidib results in decreased expression of MDM2 protein	12589031
D004999	Amifostine	Amifostine results in decreased expression of MDM2 mRNA	14555708
D000643	Ammonium Chloride	Ammonium Chloride results in increased expression of MDM2 mRNA	12420312
D000643	Ammonium Chloride	Ammonium Chloride results in increased expression of MDM2 protein	16483693
D000661	Amphetamine	Amphetamine results in increased expression of MDM2 mRNA	30779732
D000677	Amsacrine	MDM2 promoter SNP results in decreased susceptibility to Amsacrine	17575151
D000732	Androstanols	Androstanols inhibits the reaction [DDT results in increased expression of MDM2 mRNA]	23684557
D001151	Arsenic	Arsenic affects the methylation of MDM2 gene	25304211
D001151	Arsenic	MDM2 SNP affects the susceptibility to Arsenic	21982800
D000077237	Arsenic Trioxide	Arsenic Trioxide results in decreased expression of MDM2 mRNA	20458559
D000077237	Arsenic Trioxide	Arsenic Trioxide results in increased expression of MDM2 mRNA	20862710; 25574600; 26705709;
D000077237	Arsenic Trioxide	Arsenic Trioxide results in decreased expression of MDM2 mRNA	21145380
D000077237	Arsenic Trioxide	Arsenic Trioxide results in increased expression of MDM2 mRNA	17487067
D000077237	Arsenic Trioxide	pifithrin inhibits the reaction [Arsenic Trioxide results in increased expression of MDM2 mRNA]	17487067
C015001	arsenite	[[[arsenite results in increased activity of PRKDC protein] which results in increased phosphorylation of and results in increased activity of MAPK9 protein] promotes the reaction [MAPK9 protein binds to TP53 protein]] inhibits the reaction [MDM2 results in increased degradation of and results in decreased stability of TP53 protein]	22366412
D017636	Asbestos, Amphibole	Asbestos, Amphibole results in decreased expression of MDM2 protein	20855422
D001205	Ascorbic Acid	Ascorbic Acid inhibits the reaction [Potassium Dichromate results in decreased expression of MDM2 protein]	21262251
D001241	Aspirin	Aspirin results in decreased expression of MDM2 mRNA	20457246
D000069059	Atorvastatin	Atorvastatin results in increased expression of MDM2 protein	29630879
D001280	Atrazine	Atrazine affects the methylation of MDM2 gene	28931070
C049935	avobenzone	avobenzone results in increased expression of MDM2 mRNA	31016361
D001374	Azacitidine	Azacitidine results in increased expression of MDM2 mRNA	20823114
C030935	benz(a)anthracene	[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MDM2 mRNA	27858113
D001554	Benzene	MDM2 gene polymorphism affects the reaction [CDKN2A gene polymorphism affects the susceptibility to Benzene]	19596022
D001554	Benzene	Benzene results in increased expression of MDM2 mRNA	11896287; 15342939; 15935812;
D001554	Benzene	TRP53 protein affects the reaction [Benzene results in increased expression of MDM2 mRNA]	11896287
D001554	Benzene	[Benzene co-treated with methylmercury II co-treated with Trichloroethylene] results in increased expression of MDM2 mRNA	17905399
D001564	Benzo(a)pyrene	2,4,4'-trichlorobiphenyl inhibits the reaction [Benzo(a)pyrene results in increased phosphorylation of MDM2 protein]	20840854
D001564	Benzo(a)pyrene	2,4,5,2',4',5'-hexachlorobiphenyl inhibits the reaction [Benzo(a)pyrene results in increased phosphorylation of MDM2 protein]	20840854
D001564	Benzo(a)pyrene	2,4,5,2',5'-pentachlorobiphenyl inhibits the reaction [Benzo(a)pyrene results in increased phosphorylation of MDM2 protein]	20840854
D001564	Benzo(a)pyrene	3,4,5,3',4'-pentachlorobiphenyl promotes the reaction [Benzo(a)pyrene results in increased phosphorylation of MDM2 protein]	20840854
D001564	Benzo(a)pyrene	[Benzo(a)pyrene co-treated with fluoranthene] affects the expression of MDM2 mRNA	17690111
D001564	Benzo(a)pyrene	Benzo(a)pyrene promotes the reaction [TP53 protein binds to MDM2 protein]	15625077
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in decreased expression of MDM2 mRNA	30562542
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in increased expression of and results in increased phosphorylation of MDM2 protein	18096571
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in increased expression of MDM2 mRNA	10837373; 18418871; 20106945; 21632981; 21871943; 22316170; 22889811; 25690898; 26238291; 27694624; 28461126; 30562542; 31555880;
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in increased expression of MDM2 protein	22044530
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in increased expression of MDM2 protein modified form	22044530
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in increased phosphorylation of MDM2 protein	20840854; 25744307;
D001564	Benzo(a)pyrene	Cadmium Chloride affects the reaction [Benzo(a)pyrene results in increased phosphorylation of MDM2 protein]	25744307
D001564	Benzo(a)pyrene	MAPK3 mutant form inhibits the reaction [Benzo(a)pyrene results in increased phosphorylation of MDM2 protein]	20840854
D001564	Benzo(a)pyrene	MDM2 mutant form promotes the reaction [Benzo(a)pyrene results in increased expression of TP53 protein]	20840854
D001564	Benzo(a)pyrene	Simvastatin promotes the reaction [Benzo(a)pyrene promotes the reaction [TP53 protein binds to MDM2 protein]]	15625077
D001564	Benzo(a)pyrene	TP53 affects the reaction [Benzo(a)pyrene results in increased expression of MDM2 mRNA]	10837373
D001564	Benzo(a)pyrene	U 0126 inhibits the reaction [Benzo(a)pyrene results in increased phosphorylation of MDM2 protein]	20840854
D001564	Benzo(a)pyrene	[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MDM2 mRNA	27858113
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in increased expression of MDM2 mRNA	18656336; 19146932; 19770486; 21569818; 22228805; 22610609; 23735875; 9006915;
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in decreased expression of MDM2 protein	21467743
C072019	benzo(a)pyrene diolepoxide I	benzo(a)pyrene diolepoxide I results in increased expression of MDM2 mRNA	27694624
C006703	benzo(b)fluoranthene	[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MDM2 mRNA	27858113
C006703	benzo(b)fluoranthene	benzo(b)fluoranthene results in increased expression of MDM2 mRNA	26377693
C072553	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Etoposide promotes the reaction [MDM2 protein binds to TOP2A protein]]	17575151
C072553	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of MDM2 mRNA	20061341
D019324	beta-Naphthoflavone	beta-Naphthoflavone results in increased phosphorylation of MDM2 protein	26558467
C006780	bisphenol A	bisphenol A affects the expression of MDM2 mRNA	21786754
C006780	bisphenol A	bisphenol A affects the expression of MDM2 mRNA	30903817
C006780	bisphenol A	bisphenol A results in increased expression of MDM2 mRNA	29275510
C006780	bisphenol A	bisphenol A results in increased phosphorylation of MDM2 protein	24831732
C006780	bisphenol A	Curcumin inhibits the reaction [bisphenol A results in increased phosphorylation of MDM2 protein]	24831732
C006780	bisphenol A	bisphenol A results in increased expression of MDM2 mRNA	26063408
C006780	bisphenol A	bisphenol A affects the expression of MDM2 mRNA	25181051
C006780	bisphenol A	bisphenol A results in decreased expression of MDM2 mRNA	26982218
C006780	bisphenol A	bisphenol A results in increased expression of MDM2 mRNA	30816183
D000069286	Bortezomib	Bortezomib affects the expression of MDM2 protein	12393500
D000069286	Bortezomib	Bortezomib promotes the reaction [TP53 protein binds to MDM2 protein]	12393500
D000069286	Bortezomib	Bortezomib results in increased cleavage of MDM2 protein	12393500
D000069286	Bortezomib	[CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of MDM2 protein]	12393500
C023623	brassinolide	brassinolide results in decreased expression of MDM2 protein	20833159
D002101	Cacodylic Acid	[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of MDM2 mRNA	23192986
D002101	Cacodylic Acid	Cacodylic Acid results in increased expression of MDM2 mRNA	17481689
D002104	Cadmium	Cadmium results in increased expression of MDM2 mRNA	22666406
D002104	Cadmium	Cadmium results in decreased expression of MDM2 mRNA	21467746
C028031	cadmium acetate	cadmium acetate results in increased expression of MDM2 protein	15450950
D019256	Cadmium Chloride	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Cadmium Chloride results in increased phosphorylation of MDM2 protein]	25744307
D019256	Cadmium Chloride	Cadmium Chloride affects the reaction [Benzo(a)pyrene results in increased phosphorylation of MDM2 protein]	25744307
D019256	Cadmium Chloride	Cadmium Chloride affects the reaction [Etoposide results in increased phosphorylation of MDM2 protein]	25744307
D019256	Cadmium Chloride	Cadmium Chloride affects the reaction [Fluorouracil results in increased phosphorylation of MDM2 protein]	25744307
D019256	Cadmium Chloride	Cadmium Chloride results in increased phosphorylation of MDM2 protein	25744307
D019256	Cadmium Chloride	Cadmium Chloride promotes the reaction [Methylnitronitrosoguanidine results in increased expression of MDM2 protein]	12135628
D019256	Cadmium Chloride	Cadmium Chloride results in increased expression of MDM2 mRNA	11958953; 20061341; 22314386;
D019256	Cadmium Chloride	Cadmium Chloride results in increased phosphorylation of MDM2 protein	20525538; 22314386;
D019256	Cadmium Chloride	MT1 affects the reaction [Cadmium Chloride results in increased expression of MDM2 mRNA]	11958953
D019256	Cadmium Chloride	MT2 affects the reaction [Cadmium Chloride results in increased expression of MDM2 mRNA]	11958953
D019256	Cadmium Chloride	Cadmium Chloride affects the expression of MDM2 mRNA	22110744
D019256	Cadmium Chloride	[Cadmium Chloride co-treated with diallyl disulfide] results in decreased expression of MDM2 mRNA	31077537
D019256	Cadmium Chloride	Cadmium Chloride results in decreased expression of MDM2 mRNA	31077537
D019256	Cadmium Chloride	Cadmium Chloride results in increased expression of MDM2 mRNA	23405080
D002166	Camptothecin	Camptothecin results in increased expression of MDM2 protein	17555331
D002211	Capsaicin	Capsaicin promotes the reaction [Resveratrol results in decreased expression of MDM2 protein]	19846903
D002211	Capsaicin	Capsaicin results in decreased expression of MDM2 protein	19846903
D002211	Capsaicin	Capsaicin results in increased expression of MDM2 mRNA	19502594
D002211	Capsaicin	Resveratrol promotes the reaction [Capsaicin results in decreased expression of MDM2 protein]	19846903
D002211	Capsaicin	TP53 affects the reaction [Capsaicin results in decreased expression of MDM2 protein]	19846903
D002218	Carbadox	Carbadox results in increased expression of MDM2 mRNA	26558467
D002220	Carbamazepine	Carbamazepine affects the expression of MDM2 mRNA	25979313
C006698	carbendazim	carbendazim results in decreased expression of MDM2 mRNA	26055223
C006698	carbendazim	carbendazim results in increased expression of MDM2 mRNA	25304545
D002251	Carbon Tetrachloride	Carbon Tetrachloride results in increased expression of MDM2 mRNA	31150632
D002251	Carbon Tetrachloride	schizandrin B inhibits the reaction [Carbon Tetrachloride results in increased expression of MDM2 mRNA]	31150632
D002259	Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone	Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone results in decreased expression of MDM2 mRNA	16039398
D002392	Catechin	Catechin results in decreased expression of MDM2 mRNA	23706674
D002699	Chlorambucil	Chlorambucil results in increased expression of MDM2 mRNA	17476690
C004656	chloroacetaldehyde	chloroacetaldehyde results in increased expression of MDM2 mRNA	25596134
D002737	Chloroprene	Chloroprene results in increased expression of MDM2 mRNA	23125180
D002746	Chlorpromazine	Chlorpromazine results in increased expression of MDM2 mRNA	25596134
D004390	Chlorpyrifos	Chlorpyrifos results in increased expression of MDM2 mRNA	30981936
D002794	Choline	[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased methylation of MDM2 gene	20938992
C031180	chrysene	[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MDM2 mRNA	27858113
D000077404	Cidofovir	Cidofovir affects the expression of MDM2 mRNA	25596134
C012843	cinnamic aldehyde	cinnamic aldehyde results in increased expression of MDM2 mRNA	19000754
D002945	Cisplatin	[Cisplatin co-treated with 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one co-treated with Oxygen deficiency] results in increased expression of MDM2 mRNA	29690507
D002945	Cisplatin	[Cisplatin co-treated with 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one] results in increased expression of MDM2 mRNA	29690507
D002945	Cisplatin	Cisplatin promotes the reaction [TP53 protein binds to MDM2 promoter]	21552291
D002945	Cisplatin	Cisplatin promotes the reaction [TP53 protein results in increased expression of MDM2]	21552291
D002945	Cisplatin	Cisplatin results in increased activity of and results in increased expression of MDM2 protein	21624110
D002945	Cisplatin	Cisplatin results in increased expression of MDM2 mRNA	24280081; 25450742; 25596134;
D002945	Cisplatin	Cisplatin results in increased expression of MDM2 protein	16797627
D002945	Cisplatin	nutlin 3 promotes the reaction [Cisplatin results in increased activity of and results in increased expression of MDM2 protein]	21624110
D002945	Cisplatin	TP53 affects the reaction [Cisplatin results in increased activity of and results in increased expression of MDM2 protein]	21624110
D002945	Cisplatin	TP53 affects the reaction [nutlin 3 promotes the reaction [Cisplatin results in increased activity of and results in increased expression of MDM2 protein]]	21624110
D002945	Cisplatin	[TP53 protein binds to MDM2 protein] which results in decreased susceptibility to Cisplatin	21509038
D002945	Cisplatin	Cisplatin promotes the reaction [TRP53 protein results in increased expression of MDM2]	21552291
D002945	Cisplatin	Cisplatin results in increased expression of MDM2 mRNA	21151649; 24280081; 25270620;
D002945	Cisplatin	Cisplatin results in increased expression of MDM2 mRNA	24880025
D002994	Clofibrate	[Clofibrate co-treated with Acetaminophen] affects the expression of MDM2 mRNA	17585979
D002994	Clofibrate	PPARA affects the reaction [[Clofibrate co-treated with Acetaminophen] affects the expression of MDM2 mRNA]	17585979
D003035	Cobalt	Cobalt results in increased expression of MDM2 mRNA	24068677
D003035	Cobalt	TP53 protein affects the reaction [Cobalt results in increased expression of MDM2 mRNA]	24068677
C018021	cobaltous chloride	cobaltous chloride results in increased expression of MDM2 protein	19714248
C018021	cobaltous chloride	MDM2 protein promotes the reaction [cobaltous chloride inhibits the reaction [HIPK2 protein promotes the reaction [Doxorubicin results in increased phosphorylation of and results in increased activity of TP53 protein]]]	19714248
C018021	cobaltous chloride	cobaltous chloride results in increased expression of MDM2 mRNA	24386269
D003300	Copper	Copper results in increased expression of MDM2 mRNA	16629173
D003314	Corn Oil	Corn Oil results in decreased expression of MDM2 mRNA	22760963
C024015	cryptolepine	cryptolepine results in increased expression of MDM2 mRNA	16120219
C024015	cryptolepine	cryptolepine results in increased expression of MDM2 protein	16120219
D003474	Curcumin	Curcumin analog results in increased expression of MDM2 mRNA	26409325
D003474	Curcumin	Curcumin inhibits the reaction [bisphenol A results in increased phosphorylation of MDM2 protein]	24831732
D003474	Curcumin	Curcumin results in decreased expression of MDM2 mRNA	17332326
D003474	Curcumin	Curcumin results in decreased expression of MDM2 protein	17332326
D003474	Curcumin	[Curcumin results in decreased expression of MDM2 protein] which results in decreased expression of CDKN1A mRNA	17332326
C057862	cyanoginosin LR	cyanoginosin LR results in decreased expression of MDM2 mRNA	28414124
C057862	cyanoginosin LR	cyanoginosin LR results in decreased expression of MDM2 protein	28414124
C057862	cyanoginosin LR	cyanoginosin LR results in decreased expression of MDM2 protein	31157505
D016572	Cyclosporine	Cyclosporine results in increased expression of MDM2 mRNA	20106945; 25562108; 25596134;
C089595	cylindrospermopsin	cylindrospermopsin results in increased expression of MDM2 mRNA	21607682
C093628	cyproconazole	[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of MDM2 mRNA	29038839
C093628	cyproconazole	[cyproconazole co-treated with epoxiconazole] results in increased expression of MDM2 mRNA	29038839
D003634	DDT	Androstanols inhibits the reaction [DDT results in increased expression of MDM2 mRNA]	23684557
D003634	DDT	DDT results in increased expression of MDM2 mRNA	23684557
D003634	DDT	DDT results in increased expression of MDM2 protein	23684557
D000077209	Decitabine	Decitabine affects the expression of MDM2 mRNA	17145863
D003703	Demecolcine	Demecolcine results in increased expression of MDM2 mRNA	23649840
C028009	diallyl disulfide	[Cadmium Chloride co-treated with diallyl disulfide] results in decreased expression of MDM2 mRNA	31077537
C042577	diallyl trisulfide	diallyl trisulfide results in decreased expression of MDM2 protein	24415872
C042577	diallyl trisulfide	diallyl trisulfide results in increased degradation of MDM2 protein	23754639
D003976	Diazinon	Diazinon affects the expression of MDM2 mRNA	22546817
D004008	Diclofenac	Diclofenac results in decreased expression of MDM2 mRNA	17202759
D004026	Dieldrin	Dieldrin affects the expression of MDM2 mRNA	22546817
C007366	diepoxybutane	diepoxybutane inhibits the reaction [TP53 protein binds to MDM2 protein]	20024960
D004051	Diethylhexyl Phthalate	Diethylhexyl Phthalate results in decreased phosphorylation of MDM2 protein	31163220
D004051	Diethylhexyl Phthalate	Diethylhexyl Phthalate results in increased expression of MDM2 mRNA	31163220
D004052	Diethylnitrosamine	Diethylnitrosamine results in increased expression of MDM2 mRNA	17854601; 19100860; 21607683;
D004052	Diethylnitrosamine	Diethylnitrosamine results in increased expression of MDM2 protein	18506893
D004052	Diethylnitrosamine	RB1 protein inhibits the reaction [Diethylnitrosamine results in increased expression of MDM2 mRNA]	17854601
D004052	Diethylnitrosamine	[Diethylnitrosamine co-treated with 2-Acetylaminofluorene] affects the expression of and affects the localization of MDM2 protein	11003613
D004052	Diethylnitrosamine	[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of MDM2 mRNA	18544905
D004052	Diethylnitrosamine	Diethylnitrosamine results in increased expression of MDM2 mRNA	14555611; 15459018; 25242409;
D004052	Diethylnitrosamine	Diethylnitrosamine results in increased expression of MDM2 protein	14555611
D004054	Diethylstilbestrol	Diethylstilbestrol affects the mutagenesis of MDM2 gene	7916985
D004054	Diethylstilbestrol	Diethylstilbestrol results in decreased expression of MDM2 mRNA	21041162
D004054	Diethylstilbestrol	Diethylstilbestrol results in increased expression of MDM2 mRNA	15545218
D004054	Diethylstilbestrol	Diethylstilbestrol results in increased expression of MDM2 mRNA	15890375
C521105	dimethoxycurcumin	dimethoxycurcumin results in decreased expression of MDM2 protein	31513842
D004128	Dimethylnitrosamine	Dimethylnitrosamine results in increased expression of MDM2 mRNA	14600272; 15890375;
C001082	diphenylcresyl phosphate	diphenylcresyl phosphate results in increased expression of MDM2 mRNA	30981936
C001087	diphenyl methyl phosphate	diphenyl methyl phosphate results in increased expression of MDM2 mRNA	30981936
D000077143	Docetaxel	Docetaxel results in increased expression of MDM2 protein	16080190; 16797627;
C516138	dorsomorphin	[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MDM2 mRNA	27188386
C516138	dorsomorphin	[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MDM2 mRNA	27188386
C516138	dorsomorphin	[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MDM2 mRNA	27188386
D004317	Doxorubicin	Doxorubicin affects the expression of MDM2 mRNA	25529476; 29803840;
D004317	Doxorubicin	Doxorubicin inhibits the reaction [TP53 protein binds to MDM2 protein]	19351845
D004317	Doxorubicin	Doxorubicin results in increased activity of and results in increased expression of MDM2 protein	21624110
D004317	Doxorubicin	Doxorubicin results in increased expression of MDM2 mRNA	26317544
D004317	Doxorubicin	Doxorubicin results in increased expression of MDM2 protein	14665630; 17653088; 17959036; 19074854; 19560264; 26317544;
D004317	Doxorubicin	Doxorubicin results in increased phosphorylation of MDM2 protein	17935137
D004317	Doxorubicin	IFNA1 protein promotes the reaction [Doxorubicin results in increased expression of MDM2 protein]	17959036
D004317	Doxorubicin	MDM2 protein inhibits the reaction [HIPK2 protein promotes the reaction [Doxorubicin results in increased phosphorylation of and results in increased activity of TP53 protein]]	19714248
D004317	Doxorubicin	MDM2 protein promotes the reaction [cobaltous chloride inhibits the reaction [HIPK2 protein promotes the reaction [Doxorubicin results in increased phosphorylation of and results in increased activity of TP53 protein]]]	19714248
D004317	Doxorubicin	MDM2 protein results in decreased susceptibility to Doxorubicin	26317544
D004317	Doxorubicin	nutlin 3 promotes the reaction [Doxorubicin results in increased activity of and results in increased expression of MDM2 protein]	21624110
D004317	Doxorubicin	SETD7 mutant form promotes the reaction [Doxorubicin results in increased expression of MDM2 mRNA]	26317544
D004317	Doxorubicin	SETD7 mutant form promotes the reaction [Doxorubicin results in increased expression of MDM2 protein]	26317544
D004317	Doxorubicin	TP53 affects the reaction [Doxorubicin results in increased activity of and results in increased expression of MDM2 protein]	21624110
D004317	Doxorubicin	TP53 affects the reaction [nutlin 3 promotes the reaction [Doxorubicin results in increased activity of and results in increased expression of MDM2 protein]]	21624110
D004317	Doxorubicin	Wortmannin promotes the reaction [Doxorubicin results in increased phosphorylation of MDM2 protein]	17935137
D004317	Doxorubicin	Doxorubicin affects the expression of MDM2 mRNA	29653124
D004317	Doxorubicin	Doxorubicin results in increased expression of MDM2 mRNA	14766674; 16949053;
D004317	Doxorubicin	pifithrin inhibits the reaction [Doxorubicin results in increased expression of MDM2 mRNA]	14766674
D004317	Doxorubicin	Doxorubicin results in increased expression of MDM2 mRNA	12187937; 27255381;
D013759	Dronabinol	Dronabinol results in increased expression of MDM2 protein	19819240
C509867	E804 bisindole	E804 bisindole inhibits the reaction [Lipopolysaccharides results in increased expression of MDM2 mRNA]	23107598
C509867	E804 bisindole	E804 bisindole results in increased expression of MDM2 mRNA	23107598
C034192	ellipticine	MDM2 promoter SNP results in decreased susceptibility to ellipticine	17575151
D004726	Endosulfan	Endosulfan results in increased expression of MDM2 mRNA	29391264
C045651	epigallocatechin gallate	[epigallocatechin gallate co-treated with Polylactic Acid-Polyglycolic Acid Copolymer analog] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of MDM2 mRNA]	23717041
C109476	epoxiconazole	[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of MDM2 mRNA	29038839
C109476	epoxiconazole	[cyproconazole co-treated with epoxiconazole] results in increased expression of MDM2 mRNA	29038839
C109476	epoxiconazole	epoxiconazole results in increased expression of MDM2 mRNA	29038839
D004958	Estradiol	Estradiol results in decreased expression of MDM2 mRNA	24349563
D004958	Estradiol	[Estradiol co-treated with Parathion] results in increased expression of MDM2 mRNA	17622325
D004958	Estradiol	[Estradiol co-treated with TGFB1 protein] results in decreased expression of MDM2 mRNA	30165855
D004958	Estradiol	Estradiol results in increased expression of MDM2 mRNA alternative form	12168835
D004958	Estradiol	Estradiol results in increased expression of MDM2 protein	12168835
D004958	Estradiol	Estradiol results in decreased phosphorylation of MDM2 protein	22314386
D004958	Estradiol	Estradiol results in increased expression of MDM2 mRNA	23684557
D004958	Estradiol	Estradiol results in increased expression of MDM2 protein	23684557
D000431	Ethanol	Ethanol results in decreased expression of MDM2 mRNA	22535522
D004997	Ethinyl Estradiol	Ethinyl Estradiol results in increased expression of MDM2 mRNA	17606305; 29458080;
D004997	Ethinyl Estradiol	Ethinyl Estradiol results in increased expression of MDM2 mRNA alternative form	12168835
D004997	Ethinyl Estradiol	Ethinyl Estradiol results in increased expression of MDM2 protein	12168835
D004997	Ethinyl Estradiol	Ethinyl Estradiol affects the expression of MDM2 mRNA	17555576
D004997	Ethinyl Estradiol	Ethinyl Estradiol results in increased expression of MDM2 mRNA	17942748
D004997	Ethinyl Estradiol	[Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of MDM2 mRNA	17942748
C002994	ethylene dimethanesulfonate	ethylene dimethanesulfonate results in increased expression of MDM2 mRNA	22711419
D005020	Ethyl Methanesulfonate	Ethyl Methanesulfonate results in increased expression of MDM2 mRNA	23649840
D005038	Ethylnitrosourea	Ethylnitrosourea results in increased expression of MDM2 mRNA	19100860
D005038	Ethylnitrosourea	Ethylnitrosourea results in increased expression of MDM2 mRNA	15954086
D005047	Etoposide	benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Etoposide promotes the reaction [MDM2 protein binds to TOP2A protein]]	17575151
D005047	Etoposide	Cadmium Chloride affects the reaction [Etoposide results in increased phosphorylation of MDM2 protein]	25744307
D005047	Etoposide	Etoposide promotes the reaction [MDM2 protein binds to TOP2A protein]	17575151
D005047	Etoposide	Etoposide results in decreased expression of MDM2 protein	26259609
D005047	Etoposide	Etoposide results in increased expression of MDM2 mRNA	16120219; 31542801;
D005047	Etoposide	Etoposide results in increased expression of MDM2 protein	16120219; 18096571; 25078064;
D005047	Etoposide	Etoposide results in increased phosphorylation of MDM2 protein	17935137; 25744307;
D005047	Etoposide	MDM2 promoter SNP results in decreased susceptibility to Etoposide	17575151
D005047	Etoposide	Wortmannin promotes the reaction [Etoposide results in increased phosphorylation of MDM2 protein]	17935137
D005047	Etoposide	Etoposide results in increased expression of MDM2 protein	15459018
D005047	Etoposide	Tetrachlorodibenzodioxin inhibits the reaction [Etoposide results in increased expression of MDM2 protein]	15459018
C433928	EUK-134	EUK-134 inhibits the reaction [Hydrogen Peroxide results in decreased expression of MDM2 protein]	25005833
C433928	EUK-134	EUK-134 inhibits the reaction [Vitamin K 3 results in decreased expression of MDM2 protein]	25005833
D005273	Fenbendazole	Fenbendazole results in increased expression of MDM2 mRNA	23411599
D011345	Fenofibrate	Fenofibrate results in decreased expression of MDM2 mRNA	25596134
D017313	Fenretinide	Fenretinide results in decreased expression of MDM2 mRNA	16570282
D017313	Fenretinide	Fenretinide results in increased expression of MDM2 mRNA	28973697
C082360	fipronil	fipronil results in increased expression of MDM2 mRNA	23962444
D005411	Flame Retardants	Flame Retardants results in decreased expression of MDM2 mRNA	19356805
D005411	Flame Retardants	Flame Retardants results in increased expression of MDM2 mRNA	26808241
D044950	Flavanones	Flavanones results in increased phosphorylation of MDM2 protein	21616090
D005437	Flucytosine	Flucytosine results in increased expression of MDM2 protein	15592511
C007738	fluoranthene	[Benzo(a)pyrene co-treated with fluoranthene] affects the expression of MDM2 mRNA	17690111
D005472	Fluorouracil	Cadmium Chloride affects the reaction [Fluorouracil results in increased phosphorylation of MDM2 protein]	25744307
D005472	Fluorouracil	Fluorouracil promotes the reaction [N(1),N(11)-diethylnorspermine results in increased expression of MDM2 protein]	15546879
D005472	Fluorouracil	Fluorouracil results in increased expression of MDM2 mRNA	14665630; 16557594; 17982676; 22525470;
D005472	Fluorouracil	Fluorouracil results in increased expression of MDM2 protein	14665630; 15546879; 18096571; 19098008; 28785074;
D005472	Fluorouracil	Fluorouracil results in increased phosphorylation of MDM2 protein	25744307
D005472	Fluorouracil	TP53 protein promotes the reaction [Fluorouracil promotes the reaction [N(1),N(11)-diethylnorspermine results in increased expression of MDM2 protein]]	15546879
D005472	Fluorouracil	TP53 protein promotes the reaction [Fluorouracil results in increased expression of MDM2 mRNA]	17982676
D005472	Fluorouracil	TP53 protein promotes the reaction [Fluorouracil results in increased expression of MDM2 protein]	15546879
D005472	Fluorouracil	Fluorouracil results in increased expression of MDM2 mRNA	16949053
D005485	Flutamide	Flutamide results in increased expression of MDM2 mRNA	24136188
D005492	Folic Acid	Folic Acid affects the expression of MDM2 mRNA	16361273
D005492	Folic Acid	[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased methylation of MDM2 gene	20938992
D005557	Formaldehyde	Formaldehyde results in increased expression of MDM2 mRNA	18045764; 23649840;
D005557	Formaldehyde	Formaldehyde results in increased expression of MDM2 protein	18045764
D005557	Formaldehyde	Formaldehyde results in increased expression of MDM2 mRNA	18045764
C007768	formononetin	formononetin results in increased expression of MDM2 protein	28414026
D005620	Freund's Adjuvant	[Urethane co-treated with Freund's Adjuvant] results in increased expression of MDM2 mRNA	12400877
C056933	fumonisin B1	fumonisin B1 inhibits the reaction [AGT protein results in increased expression of MDM2 mRNA]	18206046
C056933	fumonisin B1	fumonisin B1 inhibits the reaction [AGT protein results in increased expression of MDM2 protein]	18206046
C039281	furan	furan results in increased expression of MDM2 mRNA	22079235
D005665	Furosemide	Furosemide affects the expression of MDM2 mRNA	17497460
D015774	Ganciclovir	Ganciclovir results in increased expression of MDM2 protein	15592511
C001277	geldanamycin	geldanamycin results in increased expression of MDM2 mRNA	26705709
C056507	gemcitabine	gemcitabine results in decreased expression of MDM2 mRNA	20103597
C056507	gemcitabine	gemcitabine results in increased expression of MDM2 mRNA	17039268
D019833	Genistein	Genistein results in increased expression of MDM2 mRNA	29458080
D019833	Genistein	Genistein results in decreased expression of MDM2 mRNA	21048042
D005839	Gentamicins	Gentamicins results in increased expression of MDM2 mRNA	22061828
C103280	goniothalamin	goniothalamin results in increased expression of MDM2 protein	20498002
C000593030	GSK-J4	GSK-J4 results in increased expression of MDM2 mRNA	29301935
C425931	GW 501516	MDM2 protein inhibits the reaction [GW 501516 results in increased activity of PPARB protein]	19103650
C500810	GW8510	GW8510 results in decreased phosphorylation of MDM2 protein	22242153
C500810	GW8510	GW8510 results in increased expression of MDM2 mRNA	22242153
D055768	Halogenated Diphenyl Ethers	Halogenated Diphenyl Ethers results in increased expression of MDM2 mRNA	26808241
C089796	hexabromocyclododecane	hexabromocyclododecane results in decreased expression of MDM2 mRNA	19356805
C070164	homocastasterone	homocastasterone results in decreased expression of MDM2 protein	20833159
D006710	Homocysteine	Homocysteine results in decreased expression of MDM2 mRNA	17326132
D006861	Hydrogen Peroxide	EUK-134 inhibits the reaction [Hydrogen Peroxide results in decreased expression of MDM2 protein]	25005833
D006861	Hydrogen Peroxide	Hydrogen Peroxide inhibits the reaction [N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in increased expression of MDM2 protein]	25005833
D006861	Hydrogen Peroxide	Hydrogen Peroxide promotes the reaction [TP53 protein binds to MDM2 promoter]	21552291
D006861	Hydrogen Peroxide	Hydrogen Peroxide promotes the reaction [TP53 protein results in increased expression of MDM2]	21552291
D006861	Hydrogen Peroxide	Hydrogen Peroxide results in decreased expression of MDM2 protein	25005833
D006861	Hydrogen Peroxide	Hydrogen Peroxide results in increased expression of MDM2 mRNA	21751221
D006861	Hydrogen Peroxide	Hydrogen Peroxide promotes the reaction [TRP53 protein results in increased expression of MDM2]	21552291
D006861	Hydrogen Peroxide	Hydrogen Peroxide results in increased expression of and affects the localization of MDM2 protein	14689451
D006861	Hydrogen Peroxide	Hydrogen Peroxide results in increased expression of MDM2 mRNA	14689451; 27525270;
D006861	Hydrogen Peroxide	Luteolin promotes the reaction [Hydrogen Peroxide results in increased expression of MDM2 mRNA]	27525270
D006861	Hydrogen Peroxide	[Quercetin co-treated with Hydrogen Peroxide] results in increased expression of MDM2 mRNA	27525270
D006918	Hydroxyurea	Hydroxyurea results in increased expression of MDM2 mRNA	18647660
D006918	Hydroxyurea	Hydroxyurea affects the expression of MDM2 protein	16356682
D006918	Hydroxyurea	Hydroxyurea results in increased expression of MDM2 mRNA	16356682
C411652	IC 261	IC 261 affects the expression of MDM2 protein	16027726
D007069	Ifosfamide	Ifosfamide results in increased expression of MDM2 mRNA	25596134
D007069	Ifosfamide	MDM2 mRNA results in decreased susceptibility to Ifosfamide	15736417
D007069	Ifosfamide	MDM2 protein results in decreased susceptibility to Ifosfamide	15736417
D007213	Indomethacin	Indomethacin results in decreased expression of MDM2 mRNA	28201806
D000077146	Irinotecan	Irinotecan metabolite results in increased expression of MDM2 mRNA	15956246
D000077146	Irinotecan	Irinotecan results in increased expression of MDM2 mRNA	15956246
D007530	Isoflurane	Isoflurane results in decreased expression of MDM2 mRNA	16978161
C544151	jinfukang	jinfukang results in decreased expression of MDM2 mRNA	27392435
C561695	(+)-JQ1 compound	(+)-JQ1 compound results in decreased expression of MDM2 mRNA	23129625
C561695	(+)-JQ1 compound	(+)-JQ1 compound results in decreased expression of MDM2 protein	23430699
C561695	(+)-JQ1 compound	MDM2 protein results in decreased susceptibility to (+)-JQ1 compound	23430699
C410337	K 7174	K 7174 results in increased expression of MDM2 mRNA	24086573
C011890	kojic acid	[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of MDM2 mRNA	18544905
D000077339	Leflunomide	Leflunomide results in increased expression of MDM2 mRNA	28988120
C038753	leptomycin B	leptomycin B results in increased expression of MDM2 mRNA	20803015
C015320	leucomalachite green	leucomalachite green results in increased phosphorylation of MDM2 protein	26558467
C533894	LG 100815	LG 100815 results in increased expression of MDM2 mRNA	16951191
C018584	linalool	linalool results in increased expression of MDM2 mRNA	19922762
C482199	lipopolysaccharide, E coli O55-B5	[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of MDM2 mRNA	18930950
D008070	Lipopolysaccharides	E804 bisindole inhibits the reaction [Lipopolysaccharides results in increased expression of MDM2 mRNA]	23107598
D008070	Lipopolysaccharides	Lipopolysaccharides results in increased expression of MDM2 mRNA	10975854; 23107598;
C000618691	LQFM030	LQFM030 results in decreased expression of MDM2 protein	27350017
C000618691	LQFM030	LQFM030 results in increased expression of MDM2 mRNA	27350017
C000628228	LQFM166	LQFM166 inhibits the reaction [TRP53 protein binds to MDM2 protein]	30057354
C010480	lupeol	lupeol inhibits the reaction [mancozeb results in increased expression of MDM2 mRNA]	27235710
D047311	Luteolin	Luteolin promotes the reaction [Hydrogen Peroxide results in increased expression of MDM2 mRNA]	27525270
D058185	Magnetite Nanoparticles	[Succimer co-treated with Magnetite Nanoparticles] results in increased expression of MDM2 mRNA	26378955
C013099	mancozeb	lupeol inhibits the reaction [mancozeb results in increased expression of MDM2 mRNA]	27235710
C013099	mancozeb	mancozeb results in increased expression of MDM2 mRNA	27235710
D008345	Manganese	[Manganese co-treated with NGF protein] results in decreased expression of MDM2 protein	25791630
D008345	Manganese	Manganese results in decreased expression of MDM2 protein	25791630
D008345	Manganese	PPM1D protein inhibits the reaction [[Manganese co-treated with NGF protein] results in decreased expression of MDM2 protein]	25791630
C025340	manganese chloride	manganese chloride results in increased expression of MDM2 mRNA	28801915
C042720	mercuric bromide	mercuric bromide results in increased expression of MDM2 mRNA	26272509
C042720	mercuric bromide	[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MDM2 mRNA	27188386
D008627	Mercuric Chloride	Mercuric Chloride results in decreased expression of MDM2 mRNA	23202902
D008687	Metformin	Metformin results in increased expression of MDM2 mRNA	25596134
D008701	Methapyrilene	Methapyrilene results in decreased expression of MDM2 mRNA	22584684
D008701	Methapyrilene	Methapyrilene results in increased expression of MDM2 mRNA	15890375; 18619722; 25242409; 26558467; 30467583;
D008701	Methapyrilene	Methapyrilene results in increased phosphorylation of MDM2 protein	26558467
D008715	Methionine	[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased methylation of MDM2 gene	20938992
D008727	Methotrexate	Methotrexate results in increased activity of and results in increased expression of MDM2 protein	21624110
D008727	Methotrexate	Methotrexate results in increased expression of MDM2 mRNA	21678067; 24449571;
D008727	Methotrexate	Methotrexate results in increased expression of MDM2 protein	17637740
D008727	Methotrexate	nutlin 3 promotes the reaction [Methotrexate results in increased activity of and results in increased expression of MDM2 protein]	21624110
D008727	Methotrexate	TP53 affects the reaction [Methotrexate results in increased activity of and results in increased expression of MDM2 protein]	21624110
D008727	Methotrexate	TP53 affects the reaction [nutlin 3 promotes the reaction [Methotrexate results in increased activity of and results in increased expression of MDM2 protein]]	21624110
D008727	Methotrexate	Methotrexate affects the expression of MDM2 mRNA	18502557
C042405	methyl caffeate	methyl caffeate binds to MDM2 protein	26415618
C005223	methyleugenol	methyleugenol results in increased expression of MDM2 mRNA	26011634
C004925	methylmercuric chloride	methylmercuric chloride results in increased expression of MDM2 mRNA	28001369
C004925	methylmercuric chloride	methylmercuric chloride results in decreased expression of MDM2 mRNA	23202902
D008767	Methylmercury Compounds	Methylmercury Compounds results in increased expression of MDM2 mRNA	20153410
C030957	methylmercury II	[Benzene co-treated with methylmercury II co-treated with Trichloroethylene] results in increased expression of MDM2 mRNA	17905399
D008741	Methyl Methanesulfonate	Methyl Methanesulfonate results in increased expression of MDM2 mRNA	23649840
D008741	Methyl Methanesulfonate	Methyl Methanesulfonate results in increased expression of MDM2 protein	25078064
D008769	Methylnitronitrosoguanidine	Methylnitronitrosoguanidine results in increased expression of MDM2 mRNA	12634122
D008769	Methylnitronitrosoguanidine	Cadmium Chloride promotes the reaction [Methylnitronitrosoguanidine results in increased expression of MDM2 protein]	12135628
D008769	Methylnitronitrosoguanidine	Methylnitronitrosoguanidine results in increased expression of MDM2 protein	12135628
D008770	Methylnitrosourea	Methylnitrosourea results in increased expression of MDM2 mRNA	28688903
C008480	methylparaoxon	methylparaoxon results in increased expression of MDM2 mRNA	18418871
D008743	Methyl Parathion	Methyl Parathion results in increased expression of MDM2 mRNA	18418871
D008777	Methyltestosterone	Methyltestosterone results in increased expression of MDM2 mRNA	29458080
C574930	MI-219	MI-219 results in decreased activity of [MDM2 protein binds to TP53 protein]	21314128
D015735	Mifepristone	Mifepristone results in increased expression of MDM2 mRNA	12605714
D016685	Mitomycin	Mitomycin results in increased expression of MDM2 protein	18096571
D016685	Mitomycin	[Mitomycin results in increased stability of TP53 protein] which results in increased expression of MDM2 mRNA	20536192
D016685	Mitomycin	Mitomycin results in increased expression of MDM2 mRNA	25270620
D008942	Mitoxantrone	MDM2 promoter SNP results in decreased susceptibility to Mitoxantrone	17575151
C000622638	MLN7243	MLN7243 results in increased sumoylation of MDM2 protein	31285264
C016599	mono-(2-ethylhexyl)phthalate	mono-(2-ethylhexyl)phthalate results in decreased expression of MDM2 protein	24706461
D016686	Monocrotaline	[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of MDM2 mRNA	21224054
C020300	monomethylarsonic acid	[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of MDM2 mRNA	23192986
C020300	monomethylarsonic acid	monomethylarsonic acid results in increased expression of MDM2 mRNA	17481689
C437683	motexafin gadolinium	motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of MDM2 mRNA]	16357179
C437683	motexafin gadolinium	motexafin gadolinium results in increased expression of MDM2 mRNA	16357179
D009151	Mustard Gas	Mustard Gas results in increased expression of MDM2 mRNA	15674843; 18955075;
D009151	Mustard Gas	Mustard Gas affects the expression of MDM2 mRNA	15651846
C059685	N(1),N(11)-diethylnorspermine	Fluorouracil promotes the reaction [N(1),N(11)-diethylnorspermine results in increased expression of MDM2 protein]	15546879
C059685	N(1),N(11)-diethylnorspermine	N(1),N(11)-diethylnorspermine results in increased expression of MDM2 protein	15546879
C059685	N(1),N(11)-diethylnorspermine	TP53 protein promotes the reaction [Fluorouracil promotes the reaction [N(1),N(11)-diethylnorspermine results in increased expression of MDM2 protein]]	15546879
C059685	N(1),N(11)-diethylnorspermine	TP53 protein promotes the reaction [N(1),N(11)-diethylnorspermine results in increased expression of MDM2 protein]	15546879
C554954	N-((3S)-1-azabicyclo(2.2.2)oct-3-yl)-1H-indazole-3-carboxamide hydrochloride	N-((3S)-1-azabicyclo(2.2.2)oct-3-yl)-1H-indazole-3-carboxamide hydrochloride results in increased expression of MDM2 mRNA	28174063
C064769	N-acetylsphingosine	N-acetylsphingosine results in decreased expression of MDM2 mRNA	18206046
C064769	N-acetylsphingosine	N-acetylsphingosine results in decreased expression of MDM2 protein	18206046
C051752	nefazodone	nefazodone results in increased expression of MDM2 mRNA	24136188
D009536	Niacinamide	Niacinamide results in increased expression of MDM2 mRNA	16998810
D009532	Nickel	Nickel results in increased expression of MDM2 mRNA	24068677
D009532	Nickel	TP53 protein affects the reaction [Nickel results in increased expression of MDM2 mRNA]	24068677
C022838	nickel chloride	nickel chloride results in increased expression of MDM2 mRNA	23566959; 28552779;
C022838	nickel chloride	TP53 protein affects the reaction [nickel chloride results in increased expression of MDM2 mRNA]	23566959
C022838	nickel chloride	nickel chloride affects the expression of MDM2 mRNA	22546817
D009534	Niclosamide	Niclosamide results in decreased expression of MDM2 mRNA	31398420
D009538	Nicotine	[Nicotine results in decreased expression of RPS27A protein] which results in increased phosphorylation of MDM2 protein	30272249
D009538	Nicotine	[[Nicotine results in decreased expression of RPS27A protein] which results in increased phosphorylation of MDM2 protein] which results in increased ubiquitination of TP53 protein	30272249
C012655	nimesulide	nimesulide results in increased expression of MDM2 mRNA	24136188
C419410	N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester	Hydrogen Peroxide inhibits the reaction [N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in increased expression of MDM2 protein]	25005833
C419410	N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester	N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in increased expression of MDM2 protein	25005833
C002741	N-nitrosomorpholine	N-nitrosomorpholine results in increased expression of MDM2 mRNA	19716841
C002741	N-nitrosomorpholine	N-nitrosomorpholine results in increased expression of MDM2 protein	14587038
C063998	nodularin	nodularin results in increased expression of MDM2 mRNA	30562542
C118989	NSC 652287	NSC 652287 results in increased expression of MDM2 mRNA	21109480
C118989	NSC 652287	NSC 652287 results in increased expression of MDM2 protein	21109480
C118989	NSC 652287	TP53 protein affects the reaction [NSC 652287 results in increased expression of MDM2 mRNA]	21109480
C118989	NSC 652287	TP53 protein promotes the reaction [NSC 652287 results in increased expression of MDM2 protein]	21109480
C482205	nutlin 3	nutlin 3 inhibits the reaction [TP53 protein binds to MDM2 protein]	21509038; 22260869;
C482205	nutlin 3	[nutlin 3 inhibits the reaction [TP53 protein binds to MDM2 protein]] which results in increased activity of TP53 protein	21509038
C482205	nutlin 3	nutlin 3 inhibits the reaction [TP73 binds to MDM2]	20422343
C482205	nutlin 3	nutlin 3 promotes the reaction [Cisplatin results in increased activity of and results in increased expression of MDM2 protein]	21624110
C482205	nutlin 3	nutlin 3 promotes the reaction [Doxorubicin results in increased activity of and results in increased expression of MDM2 protein]	21624110
C482205	nutlin 3	nutlin 3 promotes the reaction [Methotrexate results in increased activity of and results in increased expression of MDM2 protein]	21624110
C482205	nutlin 3	nutlin 3 results in increased activity of and results in increased expression of MDM2 protein	21624110
C482205	nutlin 3	nutlin 3 results in increased expression of MDM2 mRNA	21109480
C482205	nutlin 3	nutlin 3 results in increased expression of MDM2 protein	16014563; 16439685; 19098008; 21109480; 22044530;
C482205	nutlin 3	nutlin 3 results in increased expression of MDM2 protein modified form	22044530
C482205	nutlin 3	nutlin 3 results in increased susceptibility to [1-nitropyrene results in increased expression of MDM2 protein]	22044530
C482205	nutlin 3	nutlin 3 results in increased susceptibility to [1-nitropyrene results in increased expression of MDM2 protein modified form]	22044530
C482205	nutlin 3	TP53 affects the reaction [nutlin 3 promotes the reaction [Cisplatin results in increased activity of and results in increased expression of MDM2 protein]]	21624110
C482205	nutlin 3	TP53 affects the reaction [nutlin 3 promotes the reaction [Doxorubicin results in increased activity of and results in increased expression of MDM2 protein]]	21624110
C482205	nutlin 3	TP53 affects the reaction [nutlin 3 promotes the reaction [Methotrexate results in increased activity of and results in increased expression of MDM2 protein]]	21624110
C482205	nutlin 3	TP53 affects the reaction [nutlin 3 results in increased activity of and results in increased expression of MDM2 protein]	21624110
C482205	nutlin 3	TP53 protein affects the reaction [nutlin 3 results in increased expression of MDM2 protein]	16439685
C482205	nutlin 3	TP53 protein promotes the reaction [nutlin 3 results in increased expression of MDM2 mRNA]	21109480
C482205	nutlin 3	TP53 protein promotes the reaction [nutlin 3 results in increased expression of MDM2 protein]	21109480
C482205	nutlin 3	nutlin 3 results in increased expression of MDM2 mRNA	16949053
C482205	nutlin 3	nutlin 3 binds to and results in decreased activity of MDM2 protein	16014563; 21624110;
C482205	nutlin 3	nutlin 3 binds to MDM2 protein	22260869
C482205	nutlin 3	nutlin 3 inhibits the reaction [MDM2 protein binds to TP53 protein]	16014563
C482205	nutlin 3	nutlin 3 inhibits the reaction [TP53 protein binds to MDM2 protein]	22260869
C482205	nutlin 3	nutlin 3 results in decreased activity of MDM2 protein	22044530
C482205	nutlin 3	nutlin 3 results in decreased activity of [MDM2 protein binds to TP53 protein]	21314128
C042670	N-vinyl-2-pyrrolidinone	[N-vinyl-2-pyrrolidinone binds to N-vinyl-2-pyrrolidinone] which affects the expression of MDM2 mRNA	22037397
D009762	o-Aminoazotoluene	o-Aminoazotoluene results in increased expression of MDM2 mRNA	15346788
C025589	ochratoxin A	ochratoxin A results in decreased expression of MDM2 mRNA	30763683
C025589	ochratoxin A	ochratoxin A results in increased expression of MDM2 mRNA	23358140
C062198	octa-2,4,6-trienoic acid	octa-2,4,6-trienoic acid results in increased expression of MDM2 mRNA	16951191
C475587	olomoucine II	olomoucine II promotes the reaction [RPL11 protein binds to and results in decreased activity of MDM2 protein]	16003486
C016340	o,p'-DDT	o,p'-DDT affects the expression of MDM2 mRNA	18925944
D009942	Organometallic Compounds	Organometallic Compounds results in decreased expression of MDM2 protein	17210701
D000077150	Oxaliplatin	[Oxaliplatin co-treated with Topotecan] results in increased expression of MDM2 mRNA	25729387
D000077150	Oxaliplatin	Oxaliplatin results in increased expression of MDM2 mRNA	25729387
C011030	oxfendazole	oxfendazole results in decreased phosphorylation of MDM2 protein	26558467
C011030	oxfendazole	oxfendazole results in increased expression of MDM2 mRNA	26558467
D010100	Oxygen	alpha-naphthoflavone inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [Oxygen deficiency results in increased expression of MDM2 mRNA]]	19578757
D010100	Oxygen	[Cisplatin co-treated with 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one co-treated with Oxygen deficiency] results in increased expression of MDM2 mRNA	29690507
D010100	Oxygen	[Oxygen deficiency co-treated with 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one] results in increased expression of MDM2 mRNA	29690507
D010100	Oxygen	Oxygen deficiency results in increased expression of MDM2 mRNA	19502547; 19578757; 25596134;
D010100	Oxygen	Oxygen deficiency results in increased expression of MDM2 protein	19578757; 19714248;
D010100	Oxygen	Tetrachlorodibenzodioxin promotes the reaction [Oxygen deficiency results in increased expression of MDM2 mRNA]	19578757
D010100	Oxygen	Tetrachlorodibenzodioxin promotes the reaction [Oxygen deficiency results in increased expression of MDM2 protein]	19578757
D010100	Oxygen	[NFE2L2 protein affects the susceptibility to Oxygen] which affects the expression of MDM2 mRNA	30529165
D017239	Paclitaxel	MDM2 protein results in decreased susceptibility to Paclitaxel	13130078
D010269	Paraquat	Paraquat results in increased expression of MDM2 mRNA	20883675
D010269	Paraquat	GPX1 protein affects the reaction [Paraquat affects the expression of MDM2 mRNA]	12654481
D010278	Parathion	[Estradiol co-treated with Parathion] results in increased expression of MDM2 mRNA	17622325
D052638	Particulate Matter	[Vehicle Emissions results in increased abundance of Particulate Matter] which results in decreased expression of MDM2 protein	28013216
D052638	Particulate Matter	[[Vehicle Emissions results in increased abundance of Particulate Matter] which results in decreased expression of MDM2 protein] which results in increased expression of TP53 protein	28013216
D052638	Particulate Matter	[Vehicle Emissions results in increased abundance of Particulate Matter] which results in increased expression of MDM2 protein	28013216
C410127	PCB 180	PCB 180 results in decreased expression of MDM2 mRNA	21703328
D020245	p-Chloromercuribenzoic Acid	[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MDM2 mRNA	27188386
D020245	p-Chloromercuribenzoic Acid	p-Chloromercuribenzoic Acid results in increased expression of MDM2 mRNA	26272509
C073402	PD 123319	PD 123319 inhibits the reaction [AGT protein results in increased expression of MDM2 mRNA]	18206046
C073402	PD 123319	PD 123319 inhibits the reaction [AGT protein results in increased expression of MDM2 protein]	18206046
D010416	Pentachlorophenol	Pentachlorophenol results in increased expression of MDM2 mRNA	23892564
C101814	perfluoro-n-undecanoic acid	perfluoro-n-undecanoic acid results in increased expression of MDM2 mRNA	23602845
C023036	perfluorooctanoic acid	perfluorooctanoic acid results in increased expression of MDM2 mRNA	19162173
C011272	perfosfamide	perfosfamide results in increased expression of MDM2	18034189
C027579	periodate-oxidized adenosine	periodate-oxidized adenosine affects the expression of MDM2 mRNA	17097637
D010634	Phenobarbital	Phenobarbital results in increased phosphorylation of MDM2 protein	19751709
D010634	Phenobarbital	NR1I3 protein affects the reaction [Phenobarbital results in increased expression of MDM2 mRNA]	19482888
D010634	Phenobarbital	NR1I3 protein promotes the reaction [Phenobarbital results in increased expression of MDM2 mRNA]	19482888
D010634	Phenobarbital	Phenobarbital results in increased expression of MDM2 mRNA	19482888; 20816995; 25145657;
D010634	Phenobarbital	Phenobarbital results in increased expression of MDM2 mRNA	25145657
D010662	Phenylmercuric Acetate	[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MDM2 mRNA	27188386
D010662	Phenylmercuric Acetate	Phenylmercuric Acetate results in increased expression of MDM2 mRNA	26272509
D010672	Phenytoin	[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of MDM2 mRNA	21224054
D010695	Phlorhizin	Phlorhizin results in decreased expression of MDM2 mRNA	22538082
C030090	phosphoramide mustard	phosphoramide mustard results in increased expression of MDM2 mRNA	26708502
C121565	pifithrin	pifithrin inhibits the reaction [Doxorubicin results in increased expression of MDM2 mRNA]	14766674
C121565	pifithrin	pifithrin inhibits the reaction [Vehicle Emissions results in decreased expression of MDM2 protein]	18940243
C121565	pifithrin	pifithrin inhibits the reaction [Arsenic Trioxide results in increased expression of MDM2 mRNA]	17487067
D010882	Piperonyl Butoxide	Piperonyl Butoxide results in increased expression of MDM2 mRNA	15890375; 22484513;
C006253	pirinixic acid	MDM2 protein affects the reaction [pirinixic acid results in increased activity of PPARA protein]	19103650
C006253	pirinixic acid	MDM2 protein promotes the reaction [[pirinixic acid results in increased activity of PPARA protein] which results in increased expression of ACOX1 mRNA]	19103650
C006253	pirinixic acid	MDM2 protein promotes the reaction [[pirinixic acid results in increased activity of PPARA protein] which results in increased expression of ANGPTL4 mRNA]	19103650
C006253	pirinixic acid	MDM2 protein promotes the reaction [[pirinixic acid results in increased activity of PPARA protein] which results in increased expression of CYP4A1 mRNA]	19103650
C006253	pirinixic acid	MDM2 protein promotes the reaction [[pirinixic acid results in increased activity of PPARA protein] which results in increased expression of EHHADH mRNA]	19103650
C006253	pirinixic acid	MDM2 protein promotes the reaction [[pirinixic acid results in increased activity of PPARA protein] which results in increased expression of FABP1 mRNA]	19103650
C006253	pirinixic acid	MDM2 protein promotes the reaction [pirinixic acid results in increased expression of PPARA protein]	19103650
C006253	pirinixic acid	pirinixic acid promotes the reaction [MDM2 protein binds to PPARA protein]	19103650
C006253	pirinixic acid	pirinixic acid promotes the reaction [[PPARA protein binds to MDM2 protein] which binds to ACOX1 promoter]	19103650
C006253	pirinixic acid	pirinixic acid promotes the reaction [[PPARA protein binds to MDM2 protein] which binds to DBI promoter]	19103650
C006253	pirinixic acid	pirinixic acid results in increased expression of MDM2 mRNA	15890375; 19162173;
D010936	Plant Extracts	Plant Extracts affects the expression of MDM2 mRNA	12878215
D010936	Plant Extracts	Plant Extracts results in increased expression of MDM2 mRNA	23557933
C108953	platycodin D	MDM2 protein inhibits the reaction [platycodin D results in increased expression of FOXO3 protein]	25431082
C108953	platycodin D	platycodin D results in decreased expression of MDM2 protein	25431082; 27432230;
C060540	polyhexamethyleneguanidine	polyhexamethyleneguanidine affects the expression of MDM2 mRNA	29337256
D000077182	Polylactic Acid-Polyglycolic Acid Copolymer	[epigallocatechin gallate co-treated with Polylactic Acid-Polyglycolic Acid Copolymer analog] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of MDM2 mRNA]	23717041
D000077182	Polylactic Acid-Polyglycolic Acid Copolymer	[theaflavin co-treated with Polylactic Acid-Polyglycolic Acid Copolymer analog] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of MDM2 mRNA]	23717041
C019536	potassium bromate	potassium bromate results in increased expression of MDM2 mRNA	30559759
D011192	Potassium Dichromate	Ascorbic Acid inhibits the reaction [Potassium Dichromate results in decreased expression of MDM2 protein]	21262251
D011192	Potassium Dichromate	Potassium Dichromate results in decreased expression of MDM2 protein	21262251
C009006	potassium perchlorate	potassium perchlorate results in decreased expression of MDM2 mRNA	29673971
D011205	Povidone	[Silver co-treated with Povidone] affects the expression of MDM2 protein	27387714
D011205	Povidone	[Silver co-treated with Povidone] results in decreased expression of MDM2 mRNA	27387714
D017035	Pravastatin	Pravastatin results in increased phosphorylation of MDM2 protein	15625077
D017035	Pravastatin	[Pravastatin results in increased phosphorylation of MDM2 protein] which results in increased degradation of TP53 protein	15625077
D017035	Pravastatin	Sirolimus inhibits the reaction [Pravastatin results in increased phosphorylation of MDM2 protein]	15625077
D017035	Pravastatin	U 0126 inhibits the reaction [Pravastatin results in increased phosphorylation of MDM2 protein]	15625077
D017035	Pravastatin	Pravastatin results in increased expression of MDM2 protein	15625077
D011285	Pregnenolone Carbonitrile	Pregnenolone Carbonitrile results in increased expression of MDM2 mRNA	19162173
C045362	prochloraz	[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of MDM2 mRNA	29038839
C035988	procymidone	procymidone results in decreased expression of MDM2 mRNA	15686871
D011374	Progesterone	Progesterone results in increased expression of MDM2 mRNA	23012394
D011398	Promethazine	Promethazine results in increased phosphorylation of MDM2 protein	26558467
C005556	propionaldehyde	propionaldehyde results in increased expression of MDM2 mRNA	26079696
C014175	pyrazolo(3,4-d)pyrimidine	pyrazolo(3,4-d)pyrimidine analog affects the expression of MDM2 mRNA	21152443
C010423	pyrithione zinc	pyrithione zinc results in increased expression of MDM2 mRNA	21424779
D011794	Quercetin	Quercetin results in decreased expression of MDM2 protein	21933852
D011794	Quercetin	Quercetin results in decreased phosphorylation of and results in decreased expression of MDM2 protein	17973296
D011794	Quercetin	Quercetin results in increased expression of MDM2 mRNA	21632981; 23727915; 24849437;
D011794	Quercetin	[Quercetin co-treated with Hydrogen Peroxide] results in increased expression of MDM2 mRNA	27525270
D017382	Reactive Oxygen Species	[[[CD40LG protein co-treated with IL4 protein] results in increased abundance of Reactive Oxygen Species] which results in increased expression of and results in increased phosphorylation of and results in increased stability of TP53 protein] which results in increased expression of MDM2 protein	27634759
D000077185	Resveratrol	Capsaicin promotes the reaction [Resveratrol results in decreased expression of MDM2 protein]	19846903
D000077185	Resveratrol	EGF protein inhibits the reaction [Resveratrol inhibits the reaction [TP53 protein binds to MDM2 protein]]	15542774
D000077185	Resveratrol	Resveratrol inhibits the reaction [TP53 protein binds to MDM2 protein]	15542774
D000077185	Resveratrol	Resveratrol promotes the reaction [Capsaicin results in decreased expression of MDM2 protein]	19846903
D000077185	Resveratrol	Resveratrol results in decreased expression of MDM2 mRNA	16998810; 20878097; 25667456;
D000077185	Resveratrol	Resveratrol results in decreased expression of MDM2 protein	19846903
D000077185	Resveratrol	Resveratrol results in increased expression of MDM2 mRNA	15280659; 15767336; 25888808;
D000077185	Resveratrol	Staurosporine inhibits the reaction [EGF protein inhibits the reaction [Resveratrol inhibits the reaction [TP53 protein binds to MDM2 protein]]]	15542774
D000077185	Resveratrol	TP53 affects the reaction [Resveratrol results in decreased expression of MDM2 protein]	19846903
D000077185	Resveratrol	Resveratrol affects the expression of MDM2 protein	16369916
D000077185	Resveratrol	Resveratrol results in increased expression of MDM2 mRNA	16081268; 16369916;
D000077185	Resveratrol	Resveratrol results in increased expression of MDM2 protein	11245472
D000077185	Resveratrol	[Resveratrol results in increased phosphorylation of TRP53 protein] inhibits the reaction [TRP53 protein binds to MDM2 protein]	11245472
C579783	RG7112	RG7112 binds to MDM2 protein	24900694
C579783	RG7112	RG7112 results in increased expression of MDM2 protein	30022047
C579783	RG7112	TP53 protein affects the reaction [RG7112 results in increased expression of MDM2 protein]	30022047
D012293	Rifampin	[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of MDM2 mRNA	21224054
D000077154	Rosiglitazone	Rosiglitazone results in increased expression of MDM2 mRNA	25596134
D012428	Ruthenium	Ruthenium results in decreased expression of MDM2 protein	17210701
D017975	Ruthenium Compounds	Ruthenium Compounds results in decreased expression of MDM2 protein	17210701
C064116	S-(1,1,2,2-tetrafluoroethyl)cysteine	S-(1,1,2,2-tetrafluoroethyl)cysteine results in increased expression of MDM2 mRNA	16678137
C015499	schizandrin B	schizandrin B inhibits the reaction [Carbon Tetrachloride results in increased expression of MDM2 mRNA]	31150632
D012822	Silicon Dioxide	Silicon Dioxide results in increased expression of MDM2 mRNA	19073995
D012834	Silver	[Silver co-treated with Povidone] affects the expression of MDM2 protein	27387714
D012834	Silver	[Silver co-treated with Povidone] results in decreased expression of MDM2 mRNA	27387714
D012834	Silver	Silver results in decreased expression of MDM2 mRNA	26014281
D018030	Silver Compounds	[ERCC4 gene mutant form results in increased susceptibility to Silver Compounds] which results in increased expression of MDM2 mRNA	29462690
D019821	Simvastatin	Simvastatin promotes the reaction [Benzo(a)pyrene promotes the reaction [TP53 protein binds to MDM2 protein]]	15625077
D019821	Simvastatin	Simvastatin results in increased phosphorylation of MDM2 protein	15625077
D020123	Sirolimus	EIF4E protein inhibits the reaction [Sirolimus results in decreased expression of MDM2 protein]	19560264
D020123	Sirolimus	Sirolimus inhibits the reaction [Pravastatin results in increased phosphorylation of MDM2 protein]	15625077
D020123	Sirolimus	Sirolimus promotes the reaction [TP73 protein binds to MDM2 promoter]	21245298
D020123	Sirolimus	Sirolimus results in decreased expression of MDM2 protein	19560264
C009277	sodium arsenate	sodium arsenate results in decreased expression of MDM2 mRNA	24349563
C009277	sodium arsenate	sodium arsenate results in increased expression of MDM2 mRNA	23922661
C009277	sodium arsenate	sodium arsenate results in increased expression of MDM2 mRNA	11353140
C017947	sodium arsenite	sodium arsenite results in increased expression of MDM2 mRNA	29361514
C017947	sodium arsenite	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [sodium arsenite results in increased expression of MDM2 protein]	28785074
C017947	sodium arsenite	MAPK1 protein promotes the reaction [sodium arsenite results in increased expression of MDM2 protein]	28785074
C017947	sodium arsenite	sodium arsenite affects the expression of MDM2 mRNA	29319823
C017947	sodium arsenite	[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of MDM2 mRNA	23192986
C017947	sodium arsenite	sodium arsenite results in increased expression of MDM2 mRNA	12016162; 28785074; 29301061;
C017947	sodium arsenite	sodium arsenite results in increased expression of MDM2 protein	11813266; 19010883; 20375080; 28785074;
C017947	sodium arsenite	sodium arsenite results in increased expression of MDM2 protein alternative form	29319823
C017947	sodium arsenite	TP53 protein mutant form inhibits the reaction [sodium arsenite results in increased expression of MDM2 mRNA]	28785074
C017947	sodium arsenite	TP53 protein promotes the reaction [sodium arsenite results in increased expression of MDM2 protein]	20375080
C017947	sodium arsenite	sodium arsenite results in decreased expression of MDM2 protein	16166651
C017947	sodium arsenite	sodium arsenite results in increased expression of MDM2 mRNA	11353140; 20477944;
C016104	sodium bichromate	sodium bichromate affects the expression of MDM2 mRNA	11960910; 22110744;
C016104	sodium bichromate	sodium bichromate results in increased expression of MDM2 mRNA	25993096
D018038	Sodium Selenite	Sodium Selenite results in increased expression of MDM2 mRNA	24383545
D000077157	Sorafenib	Sorafenib results in increased expression of MDM2 mRNA	26409325
D019311	Staurosporine	Staurosporine inhibits the reaction [EGF protein inhibits the reaction [Resveratrol inhibits the reaction [TP53 protein binds to MDM2 protein]]]	15542774
D004113	Succimer	[Succimer co-treated with Magnetite Nanoparticles] results in increased expression of MDM2 mRNA	26378955
D000077210	Sunitinib	Sunitinib results in increased expression of MDM2 mRNA	31533062
D013605	T-2 Toxin	T-2 Toxin results in increased expression of MDM2 mRNA	26141394
D013629	Tamoxifen	Tamoxifen affects the expression of MDM2 mRNA	17555576
C112765	tanespimycin	tanespimycin results in increased degradation of MDM2 protein	17157164
C030141	taurine-ursodeoxycholate conjugate	taurine-ursodeoxycholate conjugate inhibits the reaction [TGFB1 protein results in decreased expression of MDM2 protein]	14514686
C031655	tauroursodeoxycholic acid	tauroursodeoxycholic acid results in increased expression of MDM2 mRNA	15885361
C508490	TDP 521252	TDP 521252 inhibits the reaction [MDM2 protein binds to TP53 protein]	16432175
C508490	TDP 521252	TDP 521252 results in increased expression of MDM2 mRNA	16432175
C508490	TDP 521252	TDP 521252 results in increased expression of MDM2 protein	16432175
C508491	TDP 665759	TDP 665759 inhibits the reaction [MDM2 protein binds to TP53 protein]	16432175
D020122	tert-Butylhydroperoxide	tert-Butylhydroperoxide results in increased expression of MDM2 mRNA	27509014
D013739	Testosterone	Testosterone results in decreased expression of MDM2 mRNA	20403060
C045037	testosterone-3-carboxymethyloxime-bovine serum albumin conjugate	testosterone-3-carboxymethyloxime-bovine serum albumin conjugate affects the expression of MDM2 mRNA	20189893
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in decreased expression of MDM2 protein	22015590
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in decreased expression of MDM2 mRNA	24349563
D013749	Tetrachlorodibenzodioxin	alpha-naphthoflavone inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [Oxygen deficiency results in increased expression of MDM2 mRNA]]	19578757
D013749	Tetrachlorodibenzodioxin	alpha-naphthoflavone inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of MDM2 mRNA]	19578757
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin promotes the reaction [Oxygen deficiency results in increased expression of MDM2 mRNA]	19578757
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin promotes the reaction [Oxygen deficiency results in increased expression of MDM2 protein]	19578757
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in decreased expression of MDM2 mRNA	16039398
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in decreased susceptibility to [1-nitropyrene results in increased expression of MDM2 protein]	22044530
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in decreased susceptibility to [1-nitropyrene results in increased expression of MDM2 protein modified form]	22044530
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in increased expression of MDM2 mRNA	19578757
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in increased phosphorylation of MDM2 protein	19751709
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin affects the expression of MDM2 mRNA	21570461
D013749	Tetrachlorodibenzodioxin	[Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of MDM2 mRNA	17942748
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in increased expression of MDM2 mRNA	12167310; 21041162; 26290441;
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin inhibits the reaction [Etoposide results in increased expression of MDM2 protein]	15459018
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in increased degradation of MDM2 protein	15459018
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in increased expression of and results in increased phosphorylation of and results in increased activity of MDM2 protein	15459018
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in increased phosphorylation of MDM2 protein	15459018
C056068	theaflavin	[theaflavin co-treated with Polylactic Acid-Polyglycolic Acid Copolymer analog] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of MDM2 mRNA]	23717041
C056068	theaflavin	theaflavin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of MDM2 mRNA]	23717041
D013853	Thioacetamide	Thioacetamide results in increased expression of MDM2 mRNA	18619722; 22659510; 23411599; 25242409; 26011634;
D013853	Thioacetamide	Thioacetamide results in increased phosphorylation of MDM2 protein	26558467
D013893	Thiram	Thiram results in increased expression of MDM2 mRNA	20530235
C003466	thymoquinone	thymoquinone results in decreased expression of MDM2 protein	31433961
C009495	titanium dioxide	titanium dioxide results in increased expression of MDM2 mRNA	21067279
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution results in decreased expression of MDM2 mRNA	27404394; 28065790;
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution results in increased expression of MDM2 mRNA	27865774; 29501877;
D014028	Tobacco Smoke Pollution	CAVIN1 protein affects the reaction [Tobacco Smoke Pollution promotes the reaction [MDM2 protein binds to CAV1 protein]]	21705337
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution promotes the reaction [MDM2 protein binds to CAV1 protein]	21705337
D019772	Topotecan	[Oxaliplatin co-treated with Topotecan] results in increased expression of MDM2 mRNA	25729387
D019772	Topotecan	Topotecan results in increased expression of MDM2 mRNA	25729387
D014118	Toxins, Biological	Toxins, Biological affects the expression of MDM2 mRNA	19682533
D014241	Trichloroethylene	Trichloroethylene affects the expression of MDM2 mRNA	21135412
D014241	Trichloroethylene	[Benzene co-treated with methylmercury II co-treated with Trichloroethylene] results in increased expression of MDM2 mRNA	17905399
C012589	trichostatin A	trichostatin A affects the expression of MDM2 mRNA	28542535
C016805	tris(1,3-dichloro-2-propyl)phosphate	tris(1,3-dichloro-2-propyl)phosphate results in increased expression of MDM2 mRNA	26179874
C080163	trovafloxacin	[trovafloxacin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of MDM2 mRNA	18930950
C113580	U 0126	U 0126 inhibits the reaction [Benzo(a)pyrene results in increased phosphorylation of MDM2 protein]	20840854
C113580	U 0126	U 0126 inhibits the reaction [Pravastatin results in increased phosphorylation of MDM2 protein]	15625077
D014520	Urethane	[Urethane co-treated with Freund's Adjuvant] results in increased expression of MDM2 mRNA	12400877
D014580	Ursodeoxycholic Acid	MDM2 mutant form inhibits the reaction [Ursodeoxycholic Acid results in increased ubiquitination of TP53 protein]	20807506
D014580	Ursodeoxycholic Acid	MDM2 mutant form inhibits the reaction [Ursodeoxycholic Acid affects the localization of TP53 protein]	17881359
D014580	Ursodeoxycholic Acid	NR3C1 mutant form inhibits the reaction [Ursodeoxycholic Acid inhibits the reaction [TGFB1 protein results in decreased expression of MDM2 protein]]	15222754
D014580	Ursodeoxycholic Acid	NR3C2 mutant form inhibits the reaction [Ursodeoxycholic Acid inhibits the reaction [TGFB1 protein results in decreased expression of MDM2 protein]]	15222754
D014580	Ursodeoxycholic Acid	Ursodeoxycholic Acid inhibits the reaction [TGFB1 protein results in decreased expression of MDM2 protein]	14514686; 15222754;
D014580	Ursodeoxycholic Acid	Ursodeoxycholic Acid promotes the reaction [TP53 protein binds to MDM2 protein]	17881359
D014580	Ursodeoxycholic Acid	[Ursodeoxycholic Acid promotes the reaction [TP53 protein binds to MDM2 protein]] which results in increased degradation of TP53 protein	17881359
D014580	Ursodeoxycholic Acid	Ursodeoxycholic Acid results in increased expression of MDM2 mRNA	15885361
C406224	valdecoxib	valdecoxib results in increased expression of MDM2 mRNA	24136188
D014635	Valproic Acid	Valproic Acid affects the expression of MDM2 mRNA	25979313
D014635	Valproic Acid	Valproic Acid results in decreased expression of MDM2 mRNA	28001369
D014635	Valproic Acid	Valproic Acid results in increased expression of MDM2 mRNA	23179753
D001335	Vehicle Emissions	[Vehicle Emissions results in increased abundance of Particulate Matter] which results in decreased expression of MDM2 protein	28013216
D001335	Vehicle Emissions	[[Vehicle Emissions results in increased abundance of Particulate Matter] which results in decreased expression of MDM2 protein] which results in increased expression of TP53 protein	28013216
D001335	Vehicle Emissions	[Vehicle Emissions results in increased abundance of Particulate Matter] which results in increased expression of MDM2 protein	28013216
D001335	Vehicle Emissions	pifithrin inhibits the reaction [Vehicle Emissions results in decreased expression of MDM2 protein]	18940243
D001335	Vehicle Emissions	Vehicle Emissions results in decreased expression of MDM2 protein	18940243
D014750	Vincristine	Vincristine results in decreased expression of MDM2 mRNA	16001973
D014750	Vincristine	Vincristine results in increased expression of MDM2 mRNA	23649840
D014752	Vinyl Chloride	MDM2 polymorphism affects the susceptibility to Vinyl Chloride	24464562
D024483	Vitamin K 3	EUK-134 inhibits the reaction [Vitamin K 3 results in decreased expression of MDM2 protein]	25005833
D024483	Vitamin K 3	Vitamin K 3 results in decreased expression of MDM2 protein	25005833
D000077337	Vorinostat	Vorinostat results in decreased expression of MDM2 mRNA	27188386
D000077191	Wortmannin	Wortmannin promotes the reaction [Doxorubicin results in increased phosphorylation of MDM2 protein]	17935137
D000077191	Wortmannin	Wortmannin promotes the reaction [Etoposide results in increased phosphorylation of MDM2 protein]	17935137
D015215	Zidovudine	Zidovudine results in increased expression of MDM2 protein	16797627
D015032	Zinc	Zinc affects the expression of MDM2 protein	16636310
D015032	Zinc	Zinc binds to and results in increased folding of MDM2 protein	16965791
D015032	Zinc	Zinc promotes the reaction [MDM2 protein binds to MDM2 protein]	16965791
D015032	Zinc	Zinc promotes the reaction [MDM2 protein binds to MDM4 protein]	16965791
D015032	Zinc	Zinc results in increased ubiquitination of MDM2 protein	16965791
D019345	Zinc Acetate	motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of MDM2 mRNA]	16357179
D019345	Zinc Acetate	Zinc Acetate results in increased expression of MDM2 mRNA	16357179
C484848	ziyuglycoside I	ziyuglycoside I results in decreased phosphorylation of MDM2 protein	28960612

Functional annotations

Keywords

Keyword ID	Keyword Term
KW-0002	3D-structure
KW-0025	Alternative splicing
KW-0963	Cytoplasm
KW-0945	Host-virus interaction
KW-0479	Metal-binding
KW-0539	Nucleus
KW-0597	Phosphoprotein
KW-0656	Proto-oncogene
KW-1185	Reference proteome
KW-0808	Transferase
KW-0832	Ubl conjugation
KW-0833	Ubl conjugation pathway
KW-0862	Zinc
KW-0863	Zinc-finger

Interpro

InterPro ID	InterPro Term
IPR028340	Mdm2
IPR015459	MDM2_E3_ligase
IPR016495	p53_neg-reg_MDM_2/4
IPR036885	SWIB_MDM2_dom_sf
IPR003121	SWIB_MDM2_domain
IPR001876	Znf_RanBP2
IPR036443	Znf_RanBP2_sf
IPR001841	Znf_RING
IPR013083	Znf_RING/FYVE/PHD

PROSITE

PROSITE ID	PROSITE Term
PS01358	ZF_RANBP2_1
PS50199	ZF_RANBP2_2
PS50089	ZF_RING_2

Pfam

Pfam ID	Pfam Term
PF02201	SWIB
PF00641	zf-RanBP

Gene: MDM2

Basic information

Gene expression information

Gene expression in different tissues (GTEx V7)

Gene expression in different tissues (ENCODE)

Protein structural annotations

3D structure in PDB database

Protein disorder information

Orthologous information

Other genetic variants/mutations

Disease or phenotype associated information

Gene Ontology (GO)/biological pathways

GO:Molecular Function

GO:Biological Process

GO:Cellular Component

Reactome Pathway

Drugs and compounds information

Functional annotations

Keywords

Interpro

PROSITE

Pfam

Protein-protein interaction

Protein-miRNA interaction